Author Index For Volume 41

Aakhus S (abst) 507
Abboud HE: Platelet-derived growth factor and mesangial cells 581
Abe K *See* Ogahara S et al 175
Abraham WT *See* Hensen J et al 1333
Abramovici M *See* Singhal PC et al 1560
Abrass CK (abst) 705
Adams S *See* Vlahakos DV et al 1690
Adcox MJ (abst) 705
Adler SG (abst) 700, 705
Adler SG *See* Ihm C-G et al 768
Aeo G (abst) 1463
Ahlstrand C (abst) 510
Ahn CI (abst) 1453
Ahn DW (abst) 1451
Ahn JH (abst) 1449, 1449, 1452, 1454, 1456, 1462
Ahn SH (abst) 1465
Ahn SJ (abst) 1448, 1465
Ahonen J *See* Isoniemi HM et al 155
Airaghi C (abst) 1441
Akar U (abst) 1472
Akbay E (abst) 1470
Akçay G (abst) 1473
Akoğlu E (abst) 1470
Akoğlu T (abst) 1470
Akpolat T (abst) 1470
Akyazici P (abst) 1471
Alarabi AA (abst) 501
Alaupovic P (abst) 499
Albers C (abst) 488
Albini F *See* Parati G et al 37:S-24
Alexiewicz JM *See* Chervu I et al 1501
Alinovi R *See* Khalil-Manesh F et al 1192
Al-Khateeb M *See* Said R et al 414
Alkim H (abst) 1472
Allan PL *See* Watson ML et al 206
Allegra A (abst) 1444
Allemann Y (abst) 481
Allen T *See* Jerums G et al 904
Allen TJ *See* Cooper ME et al 898
Almeida ARP, Wetzels JFM, Bunnachak D, Burke TJ, Chaimovitz C, Hammond WS, Schrier RW: Acute phosphate depletion and in vitro rat proximal tubule injury: Protection by glycine and acidosis 1494
Aloisi C (abst) 1444
Alpdoğan Ö (abst) 1470
Alpers CE (abst) 701
Alpers CE, Hudkins KL, Gown AM, Johnson RJ: Enhanced expression of "muscle-specific" actin in glomerulonephritis 1134
Alpers CE *See* Floege J et al 297
Altmann J-J *See* Mal F et al 445
Al-Uzri A, Holliday MA, Gambertoglio JG, Schambelan M, Kogan BA, Don BR: An accurate practical method for estimating GFR in clinical studies using a constant subcutaneous infusion (Technical Note) 1701
Alvarez RJ, Sun MJ, Haverty TP, Iozzo RV, Myers JC, Neilson EG: Biosynthetic and proliferative characteristics of tubulointerstitial fibroblasts probed with paracrine cytokines 14
Ambroso G (abst) 1446
Amento E (abst) 696
Amiel C *See* Bailly C et al 269
Amieva M *See* Furthmayr H et al 665
Ammer U (abst) 478
Amrani A *See* Baud L et al 600
An SJ (abst) 1455, 1464, 1464
Ancarani P (abst) 1446
Andersen CB (abst) 508
Andersen HK (abst) 510
Andersen NF (abst) 505
Andersen T (abst) 513
Anderson A *See* Morgan TO et al 36:S-78
Anderson PH *See* Hansen KW et al 847
Anderson PS (abst) 700
Anderson S, Rennke HG, Brenner BM, Zayas MA, Lafferty HM, Troy JL, Sandstrom DJ: Nifedipine versus fosinopril in uninephrectomized diabetic rats 891
Andrassy K (abst) 478, 488, 490, 700
Andreoli TE: *Kidney International*: Perspectives from the editors 1
Angielski S (abst) 494
Angus JA, Dyke AC, Jennings GL, Korner PI, Sudhir K, Ward JE, Wright CE: Receptor-stimulated release of endothelium-derived relaxing factor from resistance arteries in hypertension 37:S-73
Angus JA *See* Korner PI et al 37:S-38
Anidjar S, Osborne-Pellegrin M, Coutard M, Michel J-B: Arterial hypertension and aneurysmal dilatation 37:S-61
Antonucci F (abst) 1443
Apak H (abst) 1467
Apenberg S (abst) 478
Apperloo AJ (abst) 1436
Arakawa K *See* Ogahara S et al 175
Arakawa M *See* Hayashi H et al 749
Ardaillou N *See* Stefanovič V et al 1571
Ardaillou R (abst) 480
Ardaillou R, Bens M, Edgington TS: Glomerular tissue factor stimulates thromboxane synthesis in human platelets via thrombin generation 361
Ardaillou R *See* Stefanovič V et al 1571
Argiles A *See* Kerr PG et al 1035
Arik N (abst) 1469, 1470, 1471, 1472
Arinsoy T (abst) 1469, 1470, 1471, 1472
Arisoy E (abst) 1469
Arisoy N (abst) 1467
Arisoy S (abst) 1469
Arisz L (abst) 1433, 1436, 1437, 1437
Arisz L *See* Struijk DG et al 1668
Ark E (abst) 1466, 1473
Armelloni S (abst) 697
Arminio A *See* Muller GY et al 1055

Arnolda L, Minson J, Kapoor V, Pilowsky P, Llewellyn-Smith I, Chalmers J: Amino acid neurotransmitters in hypertension 37:S-2
Aronson PS (abst) 485
Arslan N (abst) 1469
Arslan S (abst) 1470
Artishevsky A (abst) 700, 705
Artishevsky A *See* Ihm C-G et al 768
Asmus G (abst) 488
Assmann KJM (abst) 1430, 1432
Assmann KJM *See* van den Born J et al 115
Ataman R (abst) 1466, 1466, 1467
Attawia MA *See* Nayak RC et al 1638
Attman P-O (abst) 499
Aulmann G (abst) 492
Aunsholt NA (abst) 506
Aurell M (abst) 500, 512, 512
Aurell M, Björck S: Determinants of progressive renal disease in diabetes mellitus 36:S-38
Austin HA *See* Choyke PL et al 1595
Avogaro A *See* Trevisan R et al 855
Avsar T (abst) 1473
Ayaz M (abst) 1466, 1466
Ayaz S (abst) 1470
Aydin AE (abst) 1471
Aykaç B (abst) 1467
Aynedjian HS *See* Wilkes BM et al 992
Ayo SH (abst) 700
Aysuna N (abst) 1466, 1467, 1473
Bach D (abst) 485
Bachman S, Peters J, Engler E, Ganten D, Mullins J: Transgenic rats carrying the mouse renin gene—Morphological characterization of a low-renin hypertension model 24
Bachmann S (abst) 478, 496
Backman U (abst) 507, 512
Badalamenti S (abst) 1446
Badr KF *See* Fischer DB et al 1155
Badr KF *See* Takahashi K et al 1245
Bae HM (abst) 1462
Bae HY (abst) 1463
Baelde JJ (abst) 700
Bagni B (abst) 1441, 1443
Bahner U (abst) 482
Baier LD *See* Tilton RG et al 778
Bailey J *See* May RC et al 1535
Bailly C, Bartlet-Bas C, Amiel C: Platelet activating factor inhibits Cl and K transport in the medullary thick ascending limb 269
Bak M *See* Barzilay J et al 723
Bakan E (abst) 1472
Bakkaloğlu A (abst) 1470, 1470
Bakker MAH *See* van den Born J et al 115
Bakris GL, Barnhill BW, Sadler R: Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection 912
Balat A (abst) 1468
Baldari S (abst) 1444
Ballardie FW *See* Brenchley PE et al 933
Ballmer PE, Weber BK, Roy-Chaudhury P, McNurlan MA, Watson H, Power DA, Garlick PJ: Elevation of albumin synthesis rates in nephrotic patients measured with [1-^{13}C]leucine 132
Bang BK (abst) 1448, 1455, 1457, 1460, 1460, 1463, 1464, 1464, 1464, 1464, 1464, 1465
Bang DS (abst) 1456
Bangstad H-J (abst) 703
Bangstad HJ *See* Dahl-Jørgensen K et al 920
Bank N *See* Wilkes BM et al 992
Baranowski RL (abst) 699
Bárány P (abst) 503, 504, 504, 505
Bardelli M (abst) 512
Barfuss DW, McCann WP, Katholi RE: Axial heterogeneity of adenosine transport and metabolism in the rabbit proximal tubule 1143
Barkeling B (abst) 503
Barnhill BW *See* Bakris GL et al 912
Barrès C, Julien C, Sassard J: Arterial pressure control in the sympathectomized rat 37:S-19
Barrett BJ, Parfrey PS, Vavasour HM, McDonald J, Kent G, Hefferton D, O'Dea F, Stone E, Reddy R, McManamon PJ: Contrast nephropathy in patients with impaired renal function: High versus low osmolar media 1274
Barrett GL, Mullins JJ: Studies on blood pressure regulation in hypertensive ren-2 transgenic rats 37:S-125
Barrett KJ *See* Vlahakos DV et al 1690
Bartel C (abst) 478
Bartlet-Bas C *See* Bailly C et al 269
Barzilay J, Warram JH, Bak M, Laffel LMB, Canessa M, Krolewski AS: Predisposition to hypertension: Risk factor nephropathy and hypertension in IDDM 723
Basler V (abst) 1445
Batlle DC *See* Nutting CW et al 166
Batsford S (abst) 495
Batur N (abst) 1468
Baud L (abst) 698
Baud L, Fouqueray B, Philippe C, Amrani A: Tumor necrosis factor alpha and mesangial cells 600
Baudoin P (abst) 1437
Baum RP (abst) 492
Baumann K (abst) 484
Bäumer K (abst) 482
Baumgart P (abst) 478
Baumgartner S (abst) 701
Bazzi C (abst) 1445
Beaugrand M *See* Mal F et al 445
Beck FX (abst) 494
Beck-Gessert S (abst) 705
Beckman JK *See* Yoshioka T et al 1008
Bedani PL (abst) 1441, 1443
Behrend M (abst) 484
Beilin LJ: Dietary salt and risk factors for cardiovascular disease 37:S-90
Beksaç M (abst) 1468, 1470
Bennett R *See* Hogg N et al 613
Bens M *See* Ardaillou R et al 361
Benstein JA *See* Lax DS et al 1527
Berardinelli L (abst) 1439
Berdeaux A, Duranteau J, Pussard E, Edouard A, Giudicelli J-F: Baroreflex control of regional vascular resistances during simulated orthostatism 37:S-29
Berden JHM (abst) 1432
Berden JHM *See* Elving LD et al 862
Berden JHM *See* van den Born J et al 115
Berg KJ (abst) 500, 507, 703
Berg U (abst) 512
Bergamaschi E *See* Khalil-Manesh F et al 1192
Berger B (abst) 496
Bergijk EC (abst) 700
Bergijk EC *See* Bruijn JA et al 5

Bergstrand A (abst) 507, 511, 511
Bergström J (abst) 501, 503
Bergström J *See* Canepa A et al 1016
Berl T, Mansour J, Veis JH: Regulation of atrial natriuretic peptide-stimulated cGMP production in the inner medulla 37
Bernasconi P (abst) 697
Berney T *See* Lemoine R et al 65
Berto P *See* Ronco C et al 1383
Bertocchi C *See* Gaspari F et al 1081
Bertolissi M (abst) 1443
Beşbaş N (abst) 1470, 1470
Bettini MC *See* Ronco C et al 1383
Betz M (abst) 486
Beuve CS, Leclercq C, Rannou F, Oliviero P, Mansier P, Chevalier B, Swynghedauw B, Charlemagne D: Remodeling of the heart (membrane proteins and collagen) in hypertensive cardiopathy 37:S-45
Bianco NE *See* Muller GY et al 1055
Bianco P *See* Kopp JB et al 56
Bichara M *See* Houillier P et al 1182
Biel K (abst) 493
Bieneck S (abst) 494
Bilgel H (abst) 1473
Bindels RJM (abst) 1434
Binswanger U (abst) 491
Birgegård G (abst) 507
Björck S *See* Aurell M et al 36:S-38
Bjøro T *See* Dahl-Jørgensen K et al 920
Blankenstijn PJ (abst) 1437
Blaser C (abst) 479, 498
Bleck J (abst) 487
Blin P *See* Ramboer I et al 37:S-67
Blumberg A, Weidmann P, Ferrari P: Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure 369
Bobik A *See* Korner PI et al 37:S-38
Bock HA (abst) 498
Bock HA, Hermle M, Brunner FP, Thiel G: Pressure dependent modulation of renin release in isolated perfused glomeruli 275
Böcker G (abst) 1434
Boeckmann W (abst) 492
Boer K (abst) 1437
Boer P (abst) 1430, 1435
Boer WH (abst) 1430
Boero R (abst) 1442, 1442
Boes A (abst) 702
Boes A *See* Wolthuis A et al 124
Bogman MJJT (abst) 1430
Bognetti E *See* Jones SL et al 1620
Bohle A (abst) 484
Böhler J (abst) 479
Bohman S-O (abst) 512
Boland R (abst) 479
Bollen C (abst) 479
Bonanno N (abst) 1444
Bonara P (abst) 1439
Bonilla-Felix M, Hamm LL, Herndon J, Vehaskari VM: Response of cortical collecting ducts from remnant kidneys to arginine vasopressin 1150
Bonjour J-P *See* Pedrotti A et al 80
Borch-Johnsen K, Nørgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving H-H: Is diabetic nephropathy an inherited complication? 719
Border WA, Noble NA, Yamamoto T, Tomooka S, Kagami S: Antagonists of transforming growth factor-β: A novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis 566
Border WA *See* Nakamura T et al 1213
Borensztein P *See* Houillier P et al 1182
Borgatti PP (abst) 1441
Boss C (abst) 495
Bostad L *See* Holm J et al 50
Bostedt A (abst) 484
Bottomly K (abst) 705
Bourgoignie JJ: Progression of renal disease: Current concepts and therapeutic approaches 36:S-61
Bourgoignie JJ *See* Green DF et al 956
Bourgoignie JJ *See* Green DF et al 1506
Bovio G (abst) 1443
Bowen-Pope DF *See* Floege J et al 297
Bowen-Pope DF *See* Johnson R et al 590
Bozfakioğlu S (abst) 1466, 1467, 1473
Bozkirli I (abst) 1473
Brancaccio D (abst) 1443
Brandi L (abst) 501, 502
Brändle E (abst) 478, 479
Brännström M (abst) 502
Brass EP *See* Hiatt WR et al 1613
Breborowicz A, Rodela H, Oreopoulos DG: Toxicity of osmotic solutes on human mesothelial cells in vitro 1280
Brecht U (abst) 491, 495
Bredl CR *See* Zager RA et al 1588
Brenchley PE, Coupes B, Short CD, O'Donoghue DJ, Ballardie FW, Mallick NP: Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy 933
Brendolan A *See* Ronco C et al 1383
Brenner BM *See* Anderson S et al 891
Bretzel RG (abst) 479
Breyer MD *See* Takeda M et al 1713
Brickner ME *See* Levy FL et al 961
Briner VA (abst) 699
Briscoe DM *See* Ford DM et al 1606
Broe MED *See* Vasilakakis DM et al 1400
Bronzieri C (abst) 1443
Brown R (abst) 704
Brown Z (abst) 695
Brownlee AA *See* Esnault VLM et al 1304
Brownlee M *See* Gupta S et al 1161
Brubacher D (abst) 701
Bruijn JA (abst) 700, 1431, 1432, 1432
Bruijn JA, Bergijk EC, de Heer E, Fleuren GJ, Hoedemaeker PJ: Induction and progression of experimental lupus nephritis: Exploration of a pathogenic pathway (Editorial Review) 5
Bruining G (abst) 1437
Brunette MG, Mailloux J, Lajeunesse D: Calcium transport by the luminal membrane of distal tubule. II. Effect of pH, electrical potential and calcium channel inhibitors 289
Brunette MG, Mailloux J, Lajeunesse D: Calcium transport through the luminal membrane of the distal tubule. I. Interrelationship with sodium 281
Brunner FP (abst) 498
Brunner FP *See* Bock HA et al 275
Brussel EMM-V *See* Freyss-Beguin MM et al 37:S-79
Buch S (abst) 701
Bucht H (abst) 511, 511

Buemi AL (abst) 1444
Buemi M (abst) 1444
Buhl M (abst) 696
Bunnachak D *See* Almeida ARP et al 1494
Buoncristiani U (abst) 1440
Burke TJ *See* Almeida ARP et al 1494
Burns A *See* Spencer SJW et al 1059
Burns M (abst) 701
Burns MW *See* Floege J et al 297
Busse R (abst) 697
Butcher EC (abst) 696
Buur T (abst) 502
Buyan N (abst) 1473
Buyssens N (abst) 1435
Byun HJ (abst) 1459
Byun HY (abst) 1456
Cabanas C *See* Hogg N et al 613
Çaglar S (abst) 1472
Çağlar Ş (abst) 1469, 1470, 1471
Caglioti A *See* Canton AD et al 951
Cahill CJ *See* Nayak RC et al 1638
Calemard E *See* Charra B et al 1286
Çalişkan S (abst) 1467, 1467
Callard P *See* Mal F et al 445
Calo L (abst) 1443
Calvet JP *See* Harding MA et al 317
Calvisi L (abst) 1447
Campbell HT *See* Rouch AJ et al 342
Canaud B *See* Kerr PG et al 1035
Canavese C (abst) 1447
Canepa A, Filho JCD, Forsberg A-M, Perfumo F, Carrea A, Gusmano R, Bergström J: Nutritional status and muscle amino acids in children with end-stage renal failure 1016
Canessa M *See* Barzilay J et al 723
Cantaluppi A (abst) 1441
Canton AD, Fuiano G, Sepe V, Caglioti A, Ferrone S: Mesangial expression of intercellular adhesion molecule-1 in primary glomerulosclerosis 951
Capasso G (abst) 1444
Capriles FI *See* Muller GY et al 1055
Caramelo C (abst) 695
Carbonell ME *See* Fernández JM et al 1029
Çarin M (abst) 1467, 1471, 1472
Carlsson MS (abst) 510
Carmines PK, Mitchell KD, Navar LG: Effects of calcium antagonists on renal hemodynamics and glomerular function 36:S-43
Carozzi S (abst) 1441
Carrea A *See* Canepa A et al 1016
Carroll HJ (abst) 1450
Casado S (abst) 695
Casati S (abst) 1446
Cavallini AR (abst) 1441
Cederholm B (abst) 509
Cedgård S (abst) 510
Çeliker H (abst) 1469
Cerrahpaşa IÜ (abst) 1467
Çetin S (abst) 1468
Cha DR (abst) 1455, 1459
Cha HK (abst) 1459
Cha YI (abst) 1455
Chae DW (abst) 1450, 1452
Chai KX *See* Jaffa AA et al 789
Chaimovitz C *See* Almeida ARP et al 1494
Chalmers J *See* Arnolda L et al 37:S-2
Chalmers JP *See* Elghozi J-L et al 37:S-1
Chan JCM *See* Santos F et al 356
Chana RS (abst) 699
Chang K *See* Ido Y et al 435
Chang KS (abst) 1450
Chang YS (abst) 1448, 1455, 1457, 1464, 1464, 1465
Chansel D (abst) 480
Chao J *See* Jaffa AA et al 789
Chao L *See* Jaffa AA et al 789
Charlemagne D *See* Beuve CS et al 37:S-45
Charra B, Calemard E, Ruffet M, Chazot C, Torrat J-C, Vanel T, Laurent G: Survival as an index of adequacy of dialysis 1286
Chazot C *See* Charra B et al 1286
Chen Y *See* Rocco MV et al 107
Chensue SW *See* Schmouder RL et al 191
Cheon RH (abst) 1450
Cheong HI (abst) 1454
Cheong HI *See* Kleppel MM et al 1629
Cherchi G (abst) 1447
Chervu I, Kiersztejn M, Alexiewicz JM, Fadda GZ, Smogorzewski M, Massry SG: Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism 1501
Cheung AHS, Sutherland DER, Gillingham KJ, McHugh LE, Moudry-Munns KC, Dunn DL, Najarian JS, Matas AJ: Simultaneous pancreas-kidney transplant versus kidney transplant alone in diabetic patients 924
Chevalier B *See* Beuve CS et al 37:S-45
Chi JG (abst) 1453
Chintala MS, Jandhyala BS: Evaluation of the efficacy of felodipine in two models of acute renal failure in dogs 36:S-94
Chiquet M (abst) 701
Chiquet M: Tenascin: An extracellular matrix protein involved in morphogenesis of epithelial organs 629
Cho BS (abst) 1453
Cho DK (abst) 1457, 1462
Cho JT (abst) 1460
Cho KB (abst) 1461
Cho KW (abst) 1451
Cho SW (abst) 1455
Cho WH (abst) 1460
Cho WY (abst) 1452, 1455, 1459
Choi EJ (abst) 1455
Choi HJ (abst) 1461
Choi IJ (abst) 1453, 1453, 1463
Choi JS (abst) 1461
Choi KC (abst) 1451
Choi KH (abst) 1448, 1450, 1456, 1458, 1459, 1462, 1463, 1463
Choi SD (abst) 1463
Choi Y (abst) 1454, 1461
Cholmakow K (abst) 483
Choyke PL, Austin HA, Frank JA, Girton ME, Diggs RL, Dwyer AJ, Miller LG, Nussenblatt R, McFarland H, Simon T: Hydrated clearance of gadolinium-DTPA as a measurement of glomerular filtration rate 1595
Christensen A-L (abst) 503
Christensen CK *See* Hansen KW et al 847
Christensen CK *See* Pederson MM et al 883
Christians U (abst) 487
Christiansen JS *See* Hansen KW et al 847
Christman JW *See* Fischer DB et al 1155

Chu KU (abst) 1460
Chun RW (abst) 1452
Chung CH (abst) 1450
Chung SH (abst) 1459
Chung TH (abst) 1453, 1457
Chung WY (abst) 1452
Chung Y (abst) 1454
Ciceri R (abst) 1446
Çiftçioğlu MA (abst) 1473
Cinotti GA (abst) 1442
Cinotti GA *See* Menè P et al 554
Cinquegrani M (abst) 1444
Cintin C (abst) 503
Cipollina MR *See* Trevisan R et al 855
Ciresi DL, Lloyd MA, Sandberg SM, Heublein DM, Edwards BS: The sodium retaining effects of cyclosporine 1599
Čižman B (abst) 695
Claesson-Welsh L *See* Heldin C-H et al 571
Clement J (abst) 1431
Cloarec-Blanchard L, Girard A, Houhou S, Grünfeld J-P, Elghozi J-L: Spectral analysis of short-term blood pressure and heart rate variability in uremic patients 37:S-14
Close CF *See* Walker JD et al 741
Clyne N (abst) 504, 504
Coe FL, Parks JH, Webb DR: Stone-forming potential of milk or calcium-fortified orange juice in idiopathic hypercalciuric adults 139
Coers W (abst) 1432
Cofano F (abst) 1446
Coffman TM *See* Smith SR et al 199
Coffman TM *See* Spurney RF et al 973
Cogno C (abst) 1439
Cohen AH *See* Khalil-Manesh F et al 1192
Cohen DI (abst) 483
Cohen Tervaert JW (abst) 1435
Çoker M (abst) 1468
Colantonio G (abst) 1443
Coleman DL (abst) 698
Coleman DL, Ruef C: Interleukin-6: An autocrine regulator of mesangial cell growth 604
Collins DM, Lambert MB, Middleton JP, Proctor RK, Davidson CJ, Newman GE, Schwab SJ: Fistula dysfunction: Effect on rapid hemodialysis 1292
Collins T *See* Fries JWU et al 584
Colmenares CJ *See* Muller GY et al 1055
Colombo D (abst) 1439
Colturi C (abst) 1445
Colussi G (abst) 1441
Conte G (abst) 1445
Conz P *See* Ronco C et al 1383
Cooper ME, Rumble JR, Allen TJ, O'Brien RC, Jerums G, Doyle AE: Antihypertensive therapy in a model combining spontaneous hypertension with diabetes 898
Cooper ME *See* Jerums G et al 904
Copley JB *See* Koenig KG et al 161
Correa-Rotter R, Hostetter TH, Manivel JC, Eddy AA, Rosenberg ME: Intrarenal distribution of clusterin following reduction of renal mass 938
Correa-Rotter R, Hostetter TH, Rosenberg ME: Renin and angiotensinogen gene expression in experimental diabetes mellitus 796
Cosio FG *See* Nahman NS Jr. et al 396
Cosseddu D (abst) 1445
Coupes B *See* Brenchley PE et al 933
Couser WG (abst) 701
Couser WG *See* Floege J et al 297
Coutard M *See* Anidjar S et al 37:S-61
Couttenye MM (abst) 1433
Creech EA *See* Smith SR et al 199
Crepaldi G *See* Fioretto P et al 813
Crepaldi G *See* Trevisan R et al 855
Cristinelli L (abst) 1440, 1440
Crowley S *See* Gupta S et al 1161
Cumming AD (abst) 699
Cura A (abst) 1467, 1468
Curatola A (abst) 1442, 1443
Cushner HM *See* Koenig KG et al 161
Cuzic S (abst) 480, 701
Cuzzola F (abst) 1442, 1443
Czekalski S (abst) 480
Daerr WH (abst) 480
D'Agostino A (abst) 1442
D'Agostino A *See* Menè P et al 554
Daha MR (abst) 695, 1431, 1435
Dahl E (abst) 509
Dahl K (abst) 507
Dahl-Jørgensen K, Bjøro T, Kierulf P, Sandvik L, Bangstad HJ, Hanssen KF: Long-term glycemic control and kidney function in insulin-dependent diabetes mellitus 920
Dahl-Jørgensen K (abst) 703
Dahlquist G *See* Rudberg S et al 822
Dakshinamurty KV (abst) 482
Dalmak S (abst) 1466, 1466
Dalva I (abst) 1468, 1470
Dalva K (abst) 1468, 1470
D'Amico G (abst) 697, 1445, 1446, 1447, 1447
Dämmrich J (abst) 482
Damsgaard EM, Frøland A, Jørgensen OD, Mogensen CE: Eight to nine year mortality in known non-insulin dependent diabetics and controls 731
Daniel TO, Kumjian DA: Platelet-derived growth factor receptors and phospholipase C activation 575
Danielson BG (abst) 500, 501, 501, 504, 504, 506, 507, 509, 512
Daret D *See* Ramboer I et al 37:S-67
Datta SK *See* Vlahakos DV et al 1690
Daugaard H (abst) 501, 501, 502, 512
Daugirdas JT *See* Nutting CW et al 166
Daul A (abst) 488
David C (abst) 480
Davidson CJ *See* Collins DM et al 1292
Davies JE *See* Ng LL et al 872
Davies M (abst) 699
Davies M, Martin J, Thomas GJ, Lovett DH: Proteinases and glomerular matrix turnover 671
Davies RW (abst) 1438
de Boland A (abst) 479
De Broe ME (abst) 1433, 1435
de Crombrugghe B (abst) 706
De Ferrari ME (abst) 1441
de Heer E (abst) 1430
de Heer E *See* Bruijn JA et al 5
de Jong PE (abst) 1436
de Leeuw PW (abst) 1436
De Paoli Vitali E (abst) 1443
De Pont JJHHM *See* Elving LD et al 862
De Rango E (abst) 1445
De Ridder L (abst) 1432

de Rooy-Roggekamp MC (abst) 1433
de Vries PMJM *See* Kouw PM et al 440
de Wolff FA (abst) 1432
de Zeeuw D (abst) 1436
de Zeeuw D, Janssen WMI, Jong PE: Atrial natriuretic factor: Its (patho)physiological significance in humans (Editorial Review) 1115
Dean JD *See* Vora JP et al 829
Decaux G *See* Soupart A et al 1662
Deckert T *See* Borch-Johnsen K et al 719
Deferrari G (abst) 1446
Degli Esposti E (abst) 1442, 1442
Deja A (abst) 488
DelBo A (abst) 1446
Delmez JA, Windus DW: Hemodialysis prescription and delivery in a metropolitan community 1023
Demirel F (abst) 1473
den Ottolander GJH (abst) 1433
Dengler HJ (abst) 480
Dengler TJ (abst) 480
Denneberg T (abst) 502, 510, 510
Denton DA *See* Tarjan E et al 37:S-97
DePierre JW (abst) 507
Deppisch R (abst) 486
Derkx FHM (abst) 1437
Dermietzel R *See* Minuth WW et al 215
Dern K (abst) 479
Desmoulière A, Gabbiani G: The cytoskeleton of arterial smooth muscle cells during human and experimental artheromatosis 37:S-87
D'Haese PC (abst) 1433
D'Haese PC *See* Vasilakakis DM et al 1400
Di Dio F (abst) 1443
Di Filippo S (abst) 1444
Di Gennaro C (abst) 1445
Di Rienzo M *See* Parati G et al 37:S-24
DiBona GF, Epstein M, Mann JS, Nordlander M: Introduction 36:S-1
Dietl P (abst) 488
Dietz JR *See* Ramirez G et al 334
Digenis PN *See* Vasilakakis DM et al 1400
Diggs RL *See* Choyke PL et al 1595
Dijkstra C (abst) 1430
Dilek K (abst) 1466, 1468
Dinarello CA: Cytokines: Agents provacateurs in hemodialysis? 683
Distler A (abst) 484, 484, 485, 696
Dixit VM: Thrombospondin and tumor necrosis factor 679
Djurup R (abst) 486
Dodds R *See* Jones SL et al 1620
Dogliani M (abst) 1447
Dolben J *See* Vora JP et al 829
Dolman KM (abst) 1431
Don BR *See* Al-Uzri A et al 1701
Donadon V *See* Trevisan R et al 855
Donker AJM (abst) 1433
Donker AJM *See* Kouw PM et al 440
Donohoe JF: Scleroderma and the kidney (Nephrology Forum) 462
Dörge SE (abst) 481
Dorhout Mees EJ (abst) 1430
Doria A *See* Trevisan R et al 855
Doucet A: Na-K-ATPase in the kidney tubule in relation to natriuresis 37:S-118
Douglas FL *See* Smith SR et al 199
Douglass D *See* Neufeld TK et al 1222
Douma CE (abst) 1437
Dousa TP *See* Rassier ME et al 88
Downie I *See* Gibson IW et al 211
Downie TT *See* Gibson IW et al 211
Doyle AE *See* Cooper ME et al 898
Draaijer P (abst) 1433
Draaijer P *See* Kooman JP et al 1041
Dransfield I *See* Hogg N et al 613
Drenckhahn D (abst) 696
Duley IT *See* Gabow PA et al 1311
Duman N (abst) 1469
Dündar S (abst) 1470, 1471, 1472
Dunn DL *See* Cheung AHS et al 924
Dunn MJ *See* Simonson MS et al 542
Duranay M (abst) 1469
Duranteau J *See* Berdeaux A et al 37:S-29
Dürer Z (abst) 1468
Dürr J *See* Hensen J et al 1333
Duval DP *See* Freyss-Beguin MM et al 37:S-79
Dworkin LD *See* Lax DS et al 1527
Dworkin LD *See* Weisstuch JM et al 36:S-33
Dwyer AJ *See* Choyke PL et al 1595
Dyke AC *See* Angus JA et al 37:S-73
Eason J *See* Moore KP et al 1543
Eberlein-Gonska M (abst) 490, 700
Ebert J *See* Takahashi K et al 1245
Ecder ST (abst) 1466, 1473
Eckardt K-U (abst) 481
Eddy A (abst) 701
Eddy AA *See* Correa-Rotter R et al 938
Edefonti A (abst) 1439
Edgar B *See* Elmfeldt D et al 36:S-54
Edgington TS *See* Ardaillou R et al 361
Edouard A *See* Berdeaux A et al 37:S-29
Edwards BS *See* Ciresi DL et al 1599
Egfjord M (abst) 501, 508, 512
Egido J (abst) 695
Egsmose C (abst) 501, 502
Ehmer B (abst) 493
Ehmke H (abst) 481, 490
Ehsani N (abst) 696
Eidemak I (abst) 505, 505, 505
Eiskjær H *See* Pedersen EB et al 36:S-82
Ejerblad S (abst) 512
Ekblom P (abst) 705
Ekblom P *See* Sorokin L et al 657
Ekim M (abst) 1471
Ekinci A (abst) 1467
El Yandouzi EH *See* Vrtovsnik F et al 983
Elbaşi A (abst) 1467
Eldegez U (abst) 1467, 1471
Elger M (abst) 481, 696
Elghozi J-L, Chalmers JP: Introduction 37:S-1
Elghozi J-L *See* Cloarec-Blanchard L et al 37:S-14
Elli A (abst) 1439
Elliott TG *See* Messent JWC et al 836
Elmfeldt D, Nordlander M, Edgar B: Renal effects of felodipine—A review 36:S-54
Elving LD, Wetzels JFM, De Pont JJHHM, Berden JHM: Is increased erythrocyte sodium-lithium countertransport a useful marker for diabetic nephropathy? 862
Emanuelsson B-M (abst) 510
Emmendörffer A (abst) 698
Endou H *See* Nosaka K et al 73

Endresen L (abst) 507
England B *See* May RC et al 1535
Engler E *See* Bachman S et al 24
Engler-Blum G (abst) 482
Ensari C (abst) 1471
Epper R (abst) 1445
Epstein M: Calcium antagonists and the kidney: Implications for renal protection 36:S-66
Epstein M *See* DiBona GF et al 36:S-1
Erbas B (abst) 1469
Erbay B (abst) 1469
Erbengi T (abst) 1473
Erden M (abst) 1467
Erduran E (abst) 1471
Erek E (abst) 1466, 1466
Eren Z (abst) 1467
Eriksson A *See* Heldin C-H et al 571
Erley C (abst) 495
Erley CM, Harrer U, Krämer BK, Risler T: Renal hemodynamics and reduction of proteinuria by a vasodilating beta blocker versus an ACE inhibitor 1297
Ernest I (abst) 510
Ernst W (abst) 479, 498
Erol C (abst) 1469
Erol O (abst) 1466
Esnault VLM, Soleimani B, Keogan MT, Brownlee AA, Jayne DRW, Lockwood CM: Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage 1304
Espinosa G (abst) 695
Eum SH (abst) 1451
Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells 375
Fabbri A (abst) 1442, 1442
Fadda GZ *See* Chervu I et al 1501
Fagugli RM (abst) 1440
Fahrenholz F (abst) 1430
Fairbanks LD (abst) 695
Falk RJ *See* Ewert BH et al 375
Fan P-Y *See* Spurney RF et al 973
Fan WW *See* Kleppel MM et al 1629
Fanelli V (abst) 1447
Fanti P (abst) 486
Farhood A *See* Truong LD et al 1676
Faronato PP *See* Fioretto P et al 813
Fauchald P (abst) 507
Faugere MC (abst) 496
Fawdry RM *See* Nankivell BJ et al 450
Fedeli L (abst) 1440
Federlin K (abst) 479
Fehrman I (abst) 505
Feingold KR (abst) 1438
Feith GW (abst) 1430
Fellin G (abst) 697, 1446
Fellström B (abst) 501, 512
Fenton S *See* Pei Y et al 1374
Feriani M *See* Ronco C et al 1383
Fernández JM, Carbonell ME, Mazzuchi N, Petruccelli D: Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients 1029
Ferrari P (abst) 481
Ferrari P *See* Blumberg A et al 369
Ferrari S (abst) 1446
Ferrario F (abst) 1447, 1447
Ferraro T *See* Tarjan E et al 37:S-97
Ferrero M (abst) 1447
Ferrone S *See* Canton AD et al 951
Fidler V (abst) 1431
Figliuzzi M (abst) 697
Filho JCD *See* Canepa A et al 1016
Findon G *See* Miller TE et al 1356
Fioretto P, Muollo B, Faronato PP, Opocher G, Trevisan R, Tiengo A, Mantero F, Remuzzi G, Crepaldi G, Nosadini R: Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes 813
Fioretto P *See* Trevisan R et al 855
Fischer DB, Christman JW, Badr KF: Fifteen-S-hydroxyeicosatetraenoic acid (15-S-HETE) antangonizes the chemotactic action and glomerular synthesis of leukotriene B4 in the rat 1155
Fischer J (abst) 484, 484
Fischer P (abst) 492
FitzGerald GA *See* Remuzzi G et al 1483
Flanigan MJ *See* Symreng T et al 1064
Flatmark A (abst) 509
Flavier J-L *See* Kerr PG et al 1035
Fleming S (abst) 699, 701
Fleuren GJ *See* Bruijn JA et al 5
Floege J (abst) 701
Floege J, Burns MW, Alpers CE, Yoshimura A, Pritzl P, Gordon K, Seifert RA, Bowen-Pope DF, Couser WG, Johnson RJ: Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model 297
Floege J *See* Johnson R et al 590
Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Ørskov H: Octreotide administration in diabetic rats: Effects on renal hypertrophy and urinary albumin excretior 805
Foged N (abst) 510
Fogo A *See* Yoshioka T et al 1008
Foidart JM (abst) 700
Folkow B *See* Lever AF et al 37:S-51
Ford DM, Briscoe DM, Shanley PF, Lum GM: Childhood membranoproliferative glomerulonephritis type I: Limited steroid therapy 1606
Fornasieri A (abst) 697
Forneris G (abst) 1442
Forsberg A-M *See* Canepa A et al 1016
Forslund T (abst) 505
Foster MH (abst) 695
Foster MH *See* Vlahakos DV et al 1690
Foulks CJ *See* Levy FL et al 961
Fouqueray B *See* Baud L et al 600
Franco V (abst) 1441
Frandsen H (abst) 505
Frank J (abst) 482
Frank JA *See* Choyke PL et al 1595
Fransen R (abst) 1430
Franz HE (abst) 483, 486, 492, 494, 495, 495
Frattola A *See* Parati G et al 37:S-24
Fredin DM *See* Takeda M et al 1713
Frei U (abst) 481, 486, 487
Frenken LAM, Wetzels JFM, Sluiter HE, Koene RAP: Evidence for renal vasodilation in pre-dialysis patients during correction of anemia by erythropoietin 384
Frey BM *See* Schaad HJ et al 420
Frey FJ *See* Schaad HJ et al 420

Freyss-Beguin MM, Brussel EMM-V, Simon JM, Duval DP: Regulation of membrane phospholipid metabolism in heart cell culture 37:S-79
Friedberg M (abst) 505, 505, 505
Friedlander G *See* Vrtovsnik F et al 983
Friedman R *See* Lopes de Faria JB et al 877
Friedrich F (abst) 488
Fries JWU, Collins T: Platelet-derived growth factor expression in a transgenic model 584
Frisenette-Fich C (abst) 504, 506
Frisina N (abst) 1444
Fritsch G (abst) 479
Frøland A *See* Damsgaard EM et al 731
Frölich JC *See* Radermacher J et al 1549
Frost L (abst) 510
Frystyk J *See* Flyvbjerg A et al 805
Fuiano G *See* Canton AD et al 951
Fulpius T *See* Lemoine R et al 65
Funder JW: Enzymes and the regulation of sodium balance 37:S 114
Fünfstück R (abst) 482
Furthmayr H, Lankes W, Amieva M: Moesin, a new cytoskeletal protein and constituent of filopodia: Its role in cellular functions 665
Fusaroli M (abst) 1442, 1442
Fushimi K *See* Sakamoto H et al 350
Fyhrquist F (abst) 505
Gabbiani G: The biology of myofibroblasts 530
Gabbiani G *See* Desmoulière A et al 37:S-87
Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease 1311
Gafter U, Kalechman Y, Sredni B: Induction of a subpopulation of suppressor cells by a single blood transfusion 143
Gahl GM (abst) 486
Galette A (abst) 486
Gall M-A *See* Parving H-H et al 758
Gallatin M (abst) 706
Galli F (abst) 1443
Gallieni M (abst) 1443
Gambertoglio JG *See* Al-Uzri A et al 1701
Ganadu M (abst) 1447
Gandini E (abst) 1445, 1447, 1447
Gaßner B (abst) 497
Ganten D (abst) 478, 496, 496
Ganten D *See* Bachman S et al 24
Gariboğlu S (abst) 1468
Garibotto G (abst) 1446
Garlick PJ *See* Ballmer PE et al 132
Gaskin G *See* Spencer SJW et al 1059
Gaspari F, Mosconi L, Viganò G, Perico N, Torre L, Virotta G, Bertocchi C, Remuzzi G, Ruggenenti P: Measurement of GFR with a single intravenous injection of nonradioactive iothalamate (Technical Note) 1081
Gattone VH II *See* Harding MA et al 317
Gavin JB *See* Miller TE et al 1356
Gawaz MP (abst) 482
Geatti O (abst) 1443
Geberth S (abst) 498
Gedik Y (abst) 1471
Geiger H (abst) 482
Geissinger B *See* Olbricht CJ et al 966
Gentile MG (abst) 1446
Gerbitz KD (abst) 705
Gherardi G (abst) 1445
Ghio L (abst) 1439
Giacchino F (abst) 1439
Giani M (abst) 1439
Gibbons N *See* Singhal PC et al 1560
Gibelli A (abst) 697
Gibson IW, Downie I, Downie TT, Han SW, More IAR, Lindop GBM: The parietal podocyte: A study of the vascular pole of the human glomerulus (Technical Note) 211
Gießelmann S (abst) 491
Gila JA (abst) 698
Gilbert P (abst) 489
Gilli P (abst) 1441, 1443
Gillingham KJ *See* Cheung AHS et al 924
Gillum D *See* Truong LD et al 1676
Giordano A (abst) 1447, 1447
Giordano F (abst) 1443
Girard A *See* Cloarec-Blanchard L et al 37:S-14
Girchev R (abst) 481
Girton ME *See* Choyke PL et al 1595
Giucastro G (abst) 1445
Giudicelli J-F *See* Berdeaux A et al 37:S-29
Giura C (abst) 1443
Gladziwa U (abst) 482, 483, 493, 1434
Gladziwa U *See* Kooman JP et al 1041
Glassock RJ (abst) 700, 705
Glassock RJ *See* Ihm C-G et al 768
Goch J (abst) 507
Gögelein H (abst) 485
Göğüş S (abst) 1470
Gökçe Ç (abst) 1469
Gökçe O (abst) 1469
Goldberg H (abst) 706
Goldfarb S *See* Rocco MV et al 107
Goldschmeding R (abst) 1431
Goldsmith DJA, Hilton PJ: Relationship between intracellular proton buffering capacity and intracellular pH 43
Gönenç F (abst) 1468, 1470
Gonick HC *See* Khalil-Manesh F et al 1192
Goodman S *See* von der Mark K et al 632
Goodman SL: $\alpha 6\beta 1$ integrin and laminin E8: An increasingly complex simple story 650
Gordon K *See* Floege J et al 297
Gosselink MAHE (abst) 1437
Götze M (abst) 478
Gould VE *See* Korhonen M et al 641
Gove C *See* Moore KP et al 1543
Gown AM *See* Alpers CE et al 1134
Grabensee B (abst) 485, 487
Grabowski P (abst) 699
Grant M *See* Neufeld TK et al 1222
Grantham JJ *See* Harding MA et al 317
Grantham JJ *See* Neufeld TK et al 1222
Grassi C (abst) 1443
Grayburn PA *See* Levy FL et al 961
Graziani G (abst) 1446
Greca GL *See* Ronco C et al 1383
Green DF, Hwang KH, Ryan US, Bourgoignie JJ: Culture of endothelial cells from baboon and human glomeruli 1506
Green DF, Resnick L, Bourgoignie JJ: HIV infects glomerular endothelial and mesangial but not epithelial cells in vitro 956

Greenwood C *See* Pei Y et al 1374
Greven J (abst) 478, 479
Grond J (abst) 702, 1431, 1432
Grond J *See* Wolthuis A et al 124
Grönhagen-Riska C (abst) 499, 503, 508
Grootendorst AF (abst) 1434
Gross P (abst) 485
Grosser S (abst) 480
Grover PK, Ryall RL, Marshall VR: Calcium oxalate crystallization in urine: Role of urate and glycosaminoglycans 149
Groves BM *See* Hensen J et al 1333
Gruber E *See* Ittel TH et al 1340
Grune T (abst) 494
Grunewald JM (abst) 483
Grunewald RW (abst) 483, 492
Grünfeld J-P *See* Cloarec-Blanchard L et al 37:S-14
Grunicke H (abst) 488
Grupe WE (abst) 1456
Grupp C (abst) 494
Grupp CT (abst) 483
Grützmacher P (abst) 496
Grzeszczak W (abst) 488
Guarena C (abst) 1442, 1442
Gudat F (abst) 1445
Guerra L (abst) 1439
Guignard J-P *See* Pedrotti A et al 80
Guillermo R (abst) 700
Guillermo R *See* Ihm C-G et al 768
Gulbins E (abst) 492
Güllü M (abst) 1468
Güllülü M (abst) 1466
Gültepe M (abst) 1468
Güneş Z (abst) 1470
Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D: Interactions of LDL and modified LDL with mesangial cells and matrix 1161
Gurland HJ (abst) 482
Gusmano R *See* Canepa A et al 1016
Gutjahr E *See* Olbricht CJ et al 966
Gyotoku Y *See* Lemoine R et al 65
Ha C-Y (abst) 1448
Ha SK (abst) 1448, 1456, 1462
Haas C (abst) 483
Haberstroh U (abst) 483, 495, 696
Hack CE (abst) 1431, 1438
Hackeng WHL (abst) 1433
Hackenthal E *See* Sakai T et al 533
Hackl A (abst) 484
Hah JO (abst) 1465
Haist K (abst) 495
Haites NE (abst) 699, 703, 706
Hakim R *See* Himmelfarb J et al 388
Halbhuber K-J (abst) 482
Halgunset J (abst) 500
Haller H (abst) 484, 484, 696
Hallmann R (abst) 696
Halse J (abst) 509
Hamamizade NM (abst) 1472
Hamm LL *See* Bonilla-Felix M et al 1150
Hammer M (abst) 508, 508
Hammond WS *See* Almeida ARP et al 1494
Hampl H (abst) 494
Hamzeh Y *See* Said R et al 414
Han DC (abst) 1455, 1458, 1459, 1459
Han DS (abst) 1448, 1456, 1458, 1459, 1462, 1463, 1463
Han HS (abst) 1461
Han JS (abst) 1453, 1454
Han SW *See* Gibson IW et al 211
Hanatani M (abst) 484
Handt S *See* Ittel TH et al 1340
Hanna JD *See* Santos F et al 356
Hannemann J (abst) 484
Hänsch GM (abst) 486, 496
Hansen FM (abst) 508
Hansen HE (abst) 502, 508, 510
Hansen KW, Christensen CK, Anderson PH, Pederson MM, Christiansen JS, Mogensen CE: Ambulatory blood pressure in microalbuminuric type 1 diabetic patients 847
Hansen KW *See* Flyvbjerg A et al 805
Hansen KW *See* Pederson MM et al 883
Hansen SI *See* Holm J et al 50
Hansen-Schmidt S (abst) 492
Hanssen KF (abst) 703
Hanssen KF *See* Dahl-Jørgensen K et al 920
Hara M *See* Ohashi K et al 1646
Haraldsson BS, Johnsson EKA, Rippe B: Glomerular permselectivity is dependent on adequate serum concentrations of orosomucoid 310
Harding MA, Gattone VH II, Grantham JJ, Calvet JP: Localization of overexposed c-*myc* mRNA in polycystic kidneys of the *cpk* mouse 317
Hardlund J (abst) 501
Harendza S (abst) 491
Harlow JE *See* Tilton RG et al 778
Harman N (abst) 1472
Harrer U *See* Erley CM et al 1297
Harris AG *See* Flyvbjerg A et al 805
Harris DCH *See* Nankivell BJ et al 450
Hartman A (abst) 703
Hasanoğlu E (abst) 1472, 1473
Haslett C (abst) 704
Hasslacher C (abst) 484
Haugen OA (abst) 500
Hauser IA (abst) 702
Häussinger D (abst) 496
Haverty TP *See* Alvarez RJ et al 14
Havu N *See* Nordlander M et al 36:S-100
Hawk CT *See* Schafer JA et al 255
Hayashi H, Karasawa R, Inn H, Saitou T, Ueno M, Nishi S, Suzuki Y, Ogino S, Maruyama Y, Kouda Y, Arakawa M: An electron microscopic study of glomeruli in Japanese patients with non-insulin dependent diabetes mellitus 749
Hayes C *See* Yanagisawa H et al 1000
Häyry P *See* Isoniemi HM et al 155
Haznedar R (abst) 1472
Hœdersdal C (abst) 505, 506
He CJ, Kanfer A: Quantification and modulation of thrombomodulin activity in isolated rat and human glomeruli 1170
Head GA: Central monoamine neurons and cardiovascular control 37:S-8
Hebert CL *See* Nahman NS Jr. et al 396
Heeger P, Wolf G, Meyers C, Sun MJ, O'Farrell SC, Krensky AM, Neilson EG: Isolation and characterization of cDNA from renal tubular epithelium encoding murine Rantes 220
Hefferton D *See* Barrett BJ et al 1274
Heidenreich S (abst) 495
Heidland A (abst) 482, 704

Heimburger O, Waniewski J, Werynski A, Lindholm B: A quantitative description of solute and fluid transport during peritoneal dialysis 1320
Heinrichs A *See* Ittel TH et al 1340
Helaakoski T (abst) 706
Heldin C-H, Östman A, Eriksson A, Siegbahn A, Claesson-Welsh L, Westermark B: Platelet-derived growth factor: Isoform-specific signaling via heterodimeric or homodimeric receptor complexes 571
Hellings SE *See* Takeda M et al 1713
Helmchen U (abst) 485, 497
Hennerkes B *See* Minuth WW et al 215
Henrich WL *See* Levy FL et al 961
Hensen J, Abraham WT, Lesneefsky EJ, Levenson B, Groves BM, Schröder K, Schrier RW, Dürr J: Atrial natriuretic peptide kinetic studies in patients with cardiac dysfunction 1333
Hercz G *See* Pei Y et al 1374
Herlitz H (abst) 510
Herlitz H: Long-term effects of felodipine in patients with reduced renal function 36:S-110
Hermle M (abst) 498
Hermle M *See* Bock HA et al 275
Hernando L (abst) 695
Herndon J *See* Bonilla-Felix M et al 1150
Herzog R (abst) 494
Heublein DM *See* Ciresi DL et al 1599
Hiatt WR, Koziol BJ, Shapiro JI, Brass EP: Carnitine metabolism during exercise in patients on chronic hemodialysis 1613
Hildebrandt F (abst) 485
Hill GS *See* Quan ZY et al 326
Hill RD *See* Messent JWC et al 836
Hilton PJ *See* Goldsmith DJA et al 43
Himmelfarb J, Zaoui P, Hakim R, Holbrook D: Modulation of granulocyte LAM-1 and MAC-1 during dialysis—A prospective, randomized controlled trial 388
Ho YD (abst) 1456
Hocher B (abst) 485
Hoedemaeker PhJ (abst) 1430
Hoedemaeker PJ (abst) 700
Hoedemaeker PJ *See* Bruijn JA et al 5
Hoefliger N *See* Vanholder R et al 1707
Hoffstedt E (abst) 506
Hofstädter F *See* Ittel TH et al 1340
Hogg N (abst) 704
Hogg N, Bennett R, Cabanas C, Dransfield I: Leukocyte integrin activation 613
Høier-Madsen M *See* Holm J et al 50
Holbrook D *See* Himmelfarb J et al 388
Holdaas H (abst) 507
Hollenbeck M (abst) 485
Holliday MA *See* Al-Uzri A et al 1701
Holm J, Hansen SI, Høier-Madsen M, Bostad L: A high-affinity folate binding protein in proximal tubule cells of human kidney 50
Holstein-Rathlou NH (abst) 508
Holthöfer H (abst) 696
Homma T *See* Takeda M et al 1713
Hommel E *See* Borch-Johnsen K et al 719
Honda K *See* Ohashi K et al 1646
Hong CD (abst) 1450, 1458
Hong SP (abst) 1450
Honkanen E (abst) 499, 503, 508
Hoover RL *See* Takeda M et al 1713
Hopfenmüller B (abst) 486
Hoppe A (abst) 492
Hoppe D (abst) 496
Hörkkö S, Savolainen MJ, Kervinen K, Kesäniemi YA: Carbamylation-induced alterations in low-density lipoprotein metabolism 1175
Hörl WH (abst) 479
Horvei G *See* Ofstad J et al 36:S-8
Hostetter TH *See* Correa-Rotter R et al 796
Hostetter TH *See* Correa-Rotter R et al 938
Hostetter TH *See* Salahudeen AK et al 183
Houhou S *See* Cloarec-Blanchard L et al 37:S-14
Houillier P, Borensztein P, Bichara M, Paillard M, Prigent A: Chronic neutral phosphate supplementation induces sustained, renal metabolic alkalosis 1182
Hoyer J (abst) 485
Huang S (abst) 704
Hudkins KL *See* Alpers CE et al 1134
Huh KB (abst) 1448
Huitema S (abst) 1432
Humphries MJ: Peptide recognition motifs involved in the binding of integrins to their ligands 645
Hupp T (abst) 498
Huwiler A (abst) 490
Huysmans FTM, van Hamersvelt HW, Sluiter HE, Wetzels JFM, Koene RAP: Acute renal effects of felodipine in hypertensive patients with kidney disease 36:S-106
Huysmans FTM *See* van Hamersvelt HW et al 36:S-73
Hwang KH *See* Green DF et al 1506
Hwang SD (abst) 1455, 1458, 1459, 1459
Hwang Y (abst) 1449
Hylander B (abst) 503, 504
Hyver SW *See* Pallone TL et al 1366
Ido Y, Tilton RG, Chang K, Pugliese G, Williamson JR: Rapid measurement of glomerular filtration rate in small animals (Technical Note) 435
Igarashi P (abst) 485
Ihm CG (abst) 700, 702, 1449, 1449, 1452, 1454, 1456, 1462
Ihm C-G, Lee GSL, Nast CC, Artishevsky A, Guillermo R, Levin PS, Glassock RJ, Adler SG: Early increased renal procallogen α1(IV) mRNA levels in streptozotocin induced diabetes 768
Iida H *See* Johnson R et al 590
Ilhan N (abst) 1469
Imai H *See* Komatsuda A et al 1204
Imbasciati E (abst) 1445
Imholz ALT (abst) 1436
Inagami T *See* Takeda M et al 1713
Ingerslev J (abst) 502
Inn H *See* Hayashi H et al 749
Iozzo RV *See* Alvarez RJ et al 14
Ipek Cingi M (abst) 1467
Irzyniec T (abst) 485
Işimer A (abst) 1470
Islam S *See* Nutting CW et al 166
Isoniemi HM, Krogerus L, van Willebrand E, Taskinen E, Ahonen J, Häyry P: Histopathological findings in well-functioning, long-term renal allografts 155
Itoh H *See* Komatsuda A et al 1204
Ittel TH, Gruber E, Heinrichs A, Handt S, Hofstädter F, Sieberth H-G: Effect of fluoride on aluminum-induced bone disease in rats with renal failure 1340
Iversen BM *See* Ofstad J et al 36:S-8
Izui S *See* Lemoine R et al 65
Jacobsen BA (abst) 511

Jaffa AA, Chai KX, Chao J, Chao L, Mayfield RK: Effects of diabetes and insulin on expression of kallikrein and renin genes in the kidney 789
Jahn B (abst) 486, 496
Jandhyala BS *See* Chintala MS et al 36:S-94
Jang TJ (abst) 1463
Janssen WMI *See* de Zeeuw D et al 1115
Jarrett RJ *See* Messent JWC et al 836
Jayne DRW *See* Esnault VLM et al 1304
Jenkins DAS (abst) 699
Jennette JC *See* Ewert BH et al 375
Jennings GL *See* Angus JA et al 37:S-73
Jensen C (abst) 503
Jensen G (abst) 512
Jensen JS *See* Borch-Johnsen K et al 719
Jensen LT (abst) 501, 502, 503
Jeong HJ (abst) 1453
Jeong MS (abst) 1448, 1451
Jeppesen L (abst) 505, 506
Jeppsson J-O (abst) 510
Jerums G, Allen T, Tsalamandris C, Cooper ME: Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy 904
Jerums G *See* Cooper ME et al 898
Joffe P (abst) 503, 503, 503
Jogestrand T (abst) 504
Johansson A-C (abst) 504
Johnsen SA (abst) 512
Johnson AM *See* Gabow PA et al 1311
Johnson R, Iida H, Yoshimura A, Floege J, Bowen-Pope DF: Platelet-derived growth factor: A potentially important cytokine in glomerular disease 590
Johnson RJ (abst) 701
Johnson RJ *See* Alpers CE et al 1134
Johnson RJ *See* Floege J et al 297
Johnsson EKA *See* Haraldsson BS et al 310
Johnston CI *See* Luft FC et al 36:S-114
Joles JA (abst) 1438
Jones C (abst) 701
Jones H (abst) 1438
Jones JM *See* Simonson MS et al 542
Jones MC (abst) 703
Jones RH *See* Gabow PA et al 1311
Jones SL, Kontessis P, Wiseman M, Dodds R, Bognetti E, Pinto J, Viberti G: Protein intake and blood glucose as modulators of GFR in hyperfiltering diabetic patients 1620
Jones SL *See* Walker JD et al 741
Jong PE *See* de Zeeuw D et al 1115
Jørgensen AF (abst) 510
Jørgensen F *See* Parving H-H et al 758
Jørgensen HE *See* Parving H-H et al 758
Jørgensen OD *See* Damsgaard EM et al 731
Jörres A (abst) 486
Jørstad S (abst) 507
Jover B *See* Mimran A et al 37:S-107
Julien C *See* Barrès C et al 37:S-19
Jungmann E (abst) 486, 492
Jutila MA (abst) 696
Kaehny WD *See* Gabow PA et al 1311
Kagami S *See* Border WA et al 566
Kågedal B (abst) 510
Kahl A (abst) 486
Kala A-R (abst) 503
Kalechman Y *See* Gafter U et al 143
Kallenberg CGM (abst) 1435
Kamper AL (abst) 499, 508
Kampf D (abst) 486
Kämpf W (abst) 492
Kanfer A *See* He CJ et al 1170
Kang CM (abst) 1449, 1460, 1465
Kang FT (abst) 1455, 1455
Kang KW (abst) 1449
Kang SH (abst) 1453
Kang S-K (abst) 1448
Kang YJ (abst) 1451
Kanwar YS *See* Watanabe Y et al 1262
Kaplan R *See* Wilkes BM et al 992
Kapoor V *See* Arnolda L et al 37:S-2
Karakullukçu F (abst) 1467
Karaoğlan Ü (abst) 1473
Karasawa R *See* Hayashi H et al 749
Karatan O (abst) 1469
Karsenty G (abst) 706
Kashgarian M, Sterzel RB: The pathobiology of the mesangium 524
Kashihara N *See* Watanabe Y et al 1262
Kashtan CE *See* Kleppel MM et al 1629
Katholi RE *See* Barfuss DW et al 1143
Katinios A *See* Magoula I et al 1349
Kato T *See* Takahashi K et al 1245
Katz M *See* Vlahakos DV et al 1690
Kavakli K (abst) 1467
Kawai R *See* Ohashi K et al 1646
Kawasaki K, Yaoita E, Yamamoto T, Kihara I: Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats 1517
Kaygisiz Z (abst) 1467
Kaysen GA (abst) 1438
Keck I (abst) 489
Keen H *See* Messent JWC et al 836
Keen H *See* Walker JD et al 741
Keller F (abst) 485
Kemmer FW (abst) 485, 487
Kent G *See* Barrett BJ et al 1274
Keogan MT *See* Esnault VLM et al 1304
Kerjaschki D: Molecular pathogenesis of membranous nephropathy (Nephrology Forum) 1090
Kerr PG, Argiles A, Flavier J-L, Canaud B, Mion CM: Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study 1035
Kervinen K *See* Hörkkö S et al 1175
Kesäniemi YA *See* Hörkkö S et al 1175
Kesteloot D (abst) 1432
Khalil-Manesh F, Gonick HC, Cohen AH, Alinovi R, Bergamaschi E, Mutti A, Rosen VJ: Experimental model of lead nephropathy. I. Continuous high-dose lead administration 1192
Khang KW (abst) 1460
Kielstein R (abst) 488
Kienle S (abst) 495, 495
Kiersztejn M *See* Chervu I et al 1501
Kierulf P *See* Dahl-Jørgensen K et al 920
Kihara I *See* Kawasaki K et al 1517
Kilburg M (abst) 491
Kilicturgay S (abst) 1473
Killen PD (abst) 706
Kim BU (abst) 1464
Kim CH (abst) 1455
Kim CY (abst) 1462
Kim FS (abst) 1455

Kim G-H (abst) 1454, 1455
Kim HC (abst) 1453, 1456, 1458, 1460
Kim HJ (abst) 1450, 1450, 1451, 1457, 1463
Kim HK (abst) 1452, 1455, 1459
Kim HS (abst) 1448, 1456, 1459, 1463, 1463
Kim JC (abst) 1457
Kim JS (abst) 1449
Kim JW (abst) 1456
Kim KR (abst) 1451
Kim KS (abst) 1456
Kim KY (abst) 1463
Kim MC (abst) 1461
Kim MJ (abst) 1449, 1449, 1452, 1453, 1454, 1456, 1462, 1462
Kim MK (abst) 1457
Kim MS (abst) 1457
Kim P (abst) 1453
Kim S (abst) 1453, 1454, 1460
Kim SB (abst) 1450, 1458
Kim SH (abst) 1457, 1462
Kim SY (abst) 1448, 1455, 1457, 1464, 1464
Kim WI (abst) 1464
Kim WJ (abst) 1450
Kim WM (abst) 1457
Kim Y (abst) 704, 1454
Kim YG (abst) 1453, 1461
Kim YI (abst) 1453, 1460
Kim YK (abst) 1448, 1448, 1456, 1458, 1459, 1462, 1463, 1463
Kim YS (abst) 1448, 1455, 1455, 1457, 1460, 1460, 1464, 1464, 1465
Kimberling WJ *See* Gabow PA et al 1311
King GL *See* Nayak RC et al 1638
Kinne R (abst) 1444
Kinne RKH (abst) 483
Kirazli S (abst) 1471, 1472
Kirchheim HR (abst) 481, 490
Kirste T (abst) 698
Klahr S *See* Reyes AA et al 100
Klahr S *See* Reyes AA et al 403
Klahr S *See* Yanagisawa H et al 1000
Klanke B *See* Radermacher J et al 1549
Klar N (abst) 1435
Klein J (abst) 486
Kleinknecht D *See* Mal F et al 445
Kleppel M (abst) 704
Kleppel MM, Fan WW, Cheong HI, Kashtan CE, Michael AF: Immunochemical studies of the Alport antigen 1629
Kliem V (abst) 486, 487
Klinger M (abst) 482, 487
Kloth S *See* Minuth WW et al 215
Klotman PE *See* Smith SR et al 199
Klotz U (abst) 482
Knoers VVAM (abst) 1430
Knudsen F (abst) 502
Knudsen L (abst) 502
Ko CW (abst) 1450
Ko KW (abst) 1453, 1454, 1461
Koçak H (abst) 1468
Koçak N (abst) 1466, 1467, 1473
Koch KM (abst) 481
Koch KM: Dialysis-related amyloidosis (Nephrology Forum) 1416
Koch M (abst) 487, 701
Koene RAP (abst) 1430
Koene RAP *See* Frenken LAM et al 384
Koene RAP *See* Huysmans FTM et al 36:S-106
Koene RAP *See* van Hamersvelt HW et al 36:S-73
Koenig KG, Lindberg JS, Zerwekh JE, Padalino PK, Cushner HM, Copley JB: Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease 161
Koeser T (abst) 487
Kofoed-Enevoldsen A: Inhibition of glomerular glucosaminyl N-deacetylase in diabetic rats 763
Kogan BA *See* Al-Uzri A et al 1701
Koh YB (abst) 1460, 1464, 1464
Köhler H (abst) 487
Kokot F (abst) 488
Köller M (abst) 496, 496
Kolmannskog F (abst) 500
Komatsuda A, Wakui H, Imai H, Nakamoto Y, Miura AB, Itoh H, Tashima Y: Renal localization of the constitutive 73-kDa heat-shock protein in normal and PAN rats 1204
Kon V *See* Takeda M et al 1713
Konieczkowski M *See* Sedor JR et al 595
Kontessis P *See* Jones SL et al 1620
Koo JH (abst) 1450
Koo WS (abst) 1448, 1455, 1457, 1464, 1464, 1465
Kool M (abst) 1433
Kooman JP (abst) 1434, 1435
Kooman JP, Wijnen JAG, Draaijer P, van Bortel LMAB, Gladziwa U, Peltenburg HG, Struyker-Boudier HAJ, van Hooff JP, Leunissen KML: Compliance and reactivity of the peripheral venous system in chronic intermittent hemodialysis 1041
Koomans HA (abst) 1430, 1434, 1435, 1436
Koomen GCM (abst) 1436, 1437, 1437
Koomen GCM *See* Struijk DG et al 1668
Koopman MG (abst) 1437, 1437
Kopeć W (abst) 487
Kopp JB, Bianco P, Young MF, Termine JD, Robey PG: Renal tubular epithelial cells express osteonectin in vivo and in vitro 56
Koray Z (abst) 1469
Korhonen M, Laitinen L, Ylänne J, Gould VE, Virtanen I: Integrins in developing, normal and malignant human kidney 641
Korner PI, Bobik A, Angus JA: Are cardiac and vascular "amplifiers" both necessary for the development of hypertension? 37:S-38
Korner PI *See* Angus JA et al 37:S-73
Koruk M (abst) 1472
Koster HPG (abst) 1434
Köster W (abst) 479
Kouda Y *See* Hayashi H et al 749
Kouw PM, Olthof CG, ter Wee PM, Oe LP, Donker AJM, Schneider H, de Vries PMJM: Assessment of post-dialysis dry weight: An application of the conductivity measurement method (Technical Note) 440
Koziol BJ *See* Hiatt WR et al 1613
Kozma V (abst) 511
Kragballe K (abst) 508
Kramarz S (abst) 487
Krämer BK *See* Erley CM et al 1297
Kramer HJ, Meyer-Lehnert H, Mohaupt M: Role of calcium in the progression of renal disease: Experimental evidence 36:S-2
Krause R (abst) 488
Krediet RT (abst) 1433, 1436, 1437

Krediet RT *See* Struijk DG et al 1668
Kreisberg JI (abst) 700
Krensky AM *See* Heeger P et al 220
Krieg RJ *See* Santos F et al 356
Kristensen JK (abst) 509
Kriz W (abst) 478, 481, 489, 696
Kriz W *See* Sakai T et al 533
Krogerus L *See* Isoniemi HM et al 155
Krogsgaard K (abst) 502
Krol MC (abst) 695
Krolewski AS *See* Barzilay J et al 723
Krzymański M (abst) 488
Kuch R (abst) 488
Kuchta G (abst) 492
Kühn B (abst) 482
Kühn R (abst) 482
Kühn W (abst) 489
Kumjian DA *See* Daniel TO et al 575
Kunkel SL (abst) 695
Kunkel SL *See* Schmouder RL et al 191
Kunzendorf U *See* Neumayer H-H et al 36:S-87
Kurkus J (abst) 509
Kurnik BRC *See* Weisberg LS et al 1408
Kurnik PB *See* Weisberg LS et al 1408
Kurtz A (abst) 481, 493
Küster S (abst) 488
Kütükçüler N (abst) 1467
Kütükçüler N (abst) 1468
Kvam FI *See* Ofstad J et al 36:S-8
Kwak KC (abst) 1455, 1455
Kwon HM (abst) 1459
Kwon HS (abst) 1451
Kwon TH (abst) 1457, 1462
Kwon YJ (abst) 1452, 1455, 1459
La Milia V (abst) 1444
Laborde K *See* Shahedi M et al 455
Lacape G *See* Ramboer I et al 37:S-67
Ladefoged S (abst) 505, 508
Ladefoged SD (abst) 502, 503, 505, 508
Laffel LMB *See* Barzilay J et al 723
Lafferty HM *See* Anderson S et al 891
Laitinen L *See* Korhonen M et al 641
Lajeunesse D *See* Brunette MG et al 281
Lajeunesse D *See* Brunette MG et al 289
Lamaziere J-MD *See* Ramboer I et al 37:S-67
Lambers A (abst) 1430
Lambert MB *See* Collins DM et al 1292
Lamberts LV (abst) 1433
Lamberts LV *See* Vasilakakis DM et al 1400
Lameire N (abst) 1432
Lamperi D (abst) 1443
Lane PH, Steffes MW, Mauer SM: Estimation of glomerular volume: A comparison of four methods (Technical Note) 1085
Lang F (abst) 488, 496
Langhans S (abst) 483
Lankes W *See* Furthmayr H et al 665
Larochelle P: Renal tubular effects of calcium antagonists 36:S-49
Larrue J *See* Ramboer I et al 37:S-67
Larsen S *See* Parving H-H et al 758
Larsson K (abst) 507
Laske V (abst) 478
Lassen A (abst) 502
Lauchert W (abst) 489
Laurent G *See* Charra B et al 1286
Lausten GS (abst) 508
Lavarda F (abst) 1445
Law N (abst) 697
Lax DS, Benstein JA, Tolbert E, Dworkin LD: Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys 1527
Le Grimellec C *See* Vrtovsnik F et al 983
Leclercq C *See* Beuve CS et al 37:S-45
LeDuc J (abst) 1431
Lee BJ (abst) 1455
Lee C-E (abst) 1453
Lee DK (abst) 1458
Lee GSL (abst) 700
Lee GSL *See* Ihm C-G et al 768
Lee HB (abst) 1455, 1458, 1459, 1459
Lee HC (abst) 1448
Lee HS (abst) 1453, 1460
Lee HW (abst) 1431
Lee HY (abst) 1448, 1451, 1456, 1458, 1459, 1462, 1463, 1463
Lee IH (abst) 1465
Lee J (abst) 1451
Lee JD (abst) 1464
Lee JJ (abst) 1449
Lee JK (abst) 1453
Lee JS (abst) 1453, 1453, 1454, 1460
Lee JT (abst) 1462
Lee JY (abst) 1451, 1451
Lee KB (abst) 1462
Lee KK (abst) 1463
Lee KU (abst) 1450
Lee KY (abst) 1460
Lee MA (abst) 478
Lee MH (abst) 1450
Lee SG (abst) 1458
Lee SH (abst) 1461
Lee SK (abst) 1452, 1458, 1459, 1459
Lee SR (abst) 1457, 1461, 1461
Lee SY (abst) 1452
Lee TW (abst) 1449, 1449, 1452, 1454, 1456, 1462
Lee YC (abst) 1450, 1452
Lee YS (abst) 1458
Lefkowith J *See* Reyes AA et al 100
Lehmann H (abst) 503
Lelongt B *See* Shahedi M et al 455
Lemkes HHPJ (abst) 1432
Lemley KV *See* Sakai T et al 533
Lemoine R, Berney T, Shibata T, Fulpius T, Gyotoku Y, Shimada H, Sawada S, Izui S: Induction of "wire-loop" lesions by murine monoclonal IgG3 cryoglobulins 65
Lemoniatou E (abst) 1433
Lemoniatou E *See* Vasilakakis DM et al 1400
Lempinen M (abst) 490
Leonardis D (abst) 1443
Leonhart KL *See* Nahman NS Jr. et al 396
Lesneefsky EJ *See* Hensen J et al 1333
Leunissen KML (abst) 1433, 1434, 1435
Leunissen KML *See* Kooman JP et al 1041
Levenson B *See* Hensen J et al 1333
Lever AF, Lyall F, Morton JJ, Folkow B: Angiotensin II, vascular structure and blood pressure 37:S-51
Levin PS *See* Ihm C-G et al 768
Levy FL, Grayburn PA, Foulks CJ, Brickner ME, Henrich WL: Improved left ventricular contractility with cool temperature hemodialysis 961

Leyssac PP (abst) 499, 508
Lezotte DC *See* Gabow PA et al 1311
Libetta C (abst) 1445
Lillevold PE (abst) 500
Lim CS (abst) 1460
Lim HE (abst) 1462
Lim IS (abst) 1452
Lim TH (abst) 1458
Lim VS *See* Symreng T et al 1064
Lin J-T *See* Rassier ME et al 88
Linari F (abst) 1445
Lindberg JS *See* Koenig KG et al 161
Lindberger K (abst) 506
Linde T (abst) 506, 509
Lindell Å (abst) 510
Lindergård B (abst) 509
Lindgren S (abst) 510
Lindh E (abst) 507
Lindholm A (abst) 505
Lindholm B *See* Heimburger O et al 1320
Lindner G (abst) 1441
Lindop GBM *See* Gibson IW et al 211
Lindqvist B (abst) 511
Lindschau C (abst) 484, 696
Lindsjö M (abst) 512
Lindström H (abst) 507
Linné T (abst) 499
Lins L-E (abst) 504
Liu E (abst) 701
Ljunghall S (abst) 507
Llewellyn-Smith I *See* Arnolda L et al 37:S-2
Lloyd MA *See* Ciresi DL et al 1599
Locatelli F (abst) 1444
Lockwood CM *See* Esnault VLM et al 1304
Lodde P (abst) 1447
Logue B *See* May RC et al 1535
Løkkegaard H (abst) 505, 513
Løkkegaard H *See* Parving H-H et al 758
Løkkegaard N (abst) 502
Lonnemann G (abst) 481
Lopes de Faria JB, Friedman R, Tariq T, Viberti GC: Prevalence of raised sodium-lithium countertransport activity in type 1 diabetic patients 877
López-Farré A (abst) 695
Lorbeer B (abst) 483
Lovett DH *See* Davies M et al 671
Lubrich-Birkner I (abst) 489
Luff SE *See* McLachlan EM et al 37:S-56
Luft FC, Johnston CI: Are calcium antagonists of value in ameliorating the course of chronic renal disease? 36:S-114
Lum GM *See* Ford DM et al 1606
Lundberg L (abst) 511
Lundberg M (abst) 502
Lupi A *See* Ronco C et al 1383
Lusenti T (abst) 1441
Lusiani L *See* Trevisan R et al 855
Lyall F *See* Lever AF et al 37:S-51
Machado IV *See* Muller GY et al 1055
Macica CM *See* Wilkes BM et al 992
Mackensen-Haen S (abst) 484
Macnicol AH *See* Watson ML et al 206
Madaio MP (abst) 695
Madaio MP *See* Vlahakos DV et al 1690
Madri JA (abst) 702, 705
Madri JA, Marx M: Matrix composition, organization and soluble factors: Modulators of microvascular cell differentiation in vitro 560
Madri JA, Sterzel RB: Introduction 523
Magil AB *See* Wakai S et al 428
Magnusson M (abst) 504
Magoula I, Tsapas G, Mavromatidis K, Katinios A: Single kidney function: Early and late changes in urate transport after nephrectomy 1349
Mailloux J *See* Brunette MG et al 281
Mailloux J *See* Brunette MG et al 289
Maiorca R (abst) 1440, 1440
Mak RHK: Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients 1049
Makino H *See* Watanabe Y et al 1262
Mal F, Meyrier A, Callard P, Kleinknecht D, Altmann J-J, Beaugrand M: The diagnostic yield of transjugular renal biopsy. Experience in 200 cases (Technical Note) 445
Malfi B (abst) 1439
Mall G (abst) 485
Mallamaci F (abst) 1443, 1444
Mallick NP *See* Brenchley PE et al 933
Malluche HH (abst) 486, 496
Maly K (abst) 488
Mályusz M (abst) 484
Mályusz T (abst) 484
Mancia G *See* Parati G et al 37:S-24
Mancini E (abst) 1446
Manivel JC *See* Correa-Rotter R et al 938
Mann H (abst) 482, 483
Mann JS *See* DiBona GF et al 36:S-1
Manna G (abst) 1446
Mansier P *See* Beuve CS et al 37:S-45
Manson WJ (abst) 1435
Mansour J *See* Berl T et al 37
Mantero F *See* Fioretto P et al 813
Manuel A *See* Pei Y et al 1374
Manzione A (abst) 1439
Marabini M (abst) 1446
Marangella M (abst) 1445
Marcussen N (abst) 499
Markovic-Lipkovski J (abst) 489, 489
Marshall SM *See* Flyvbjerg A et al 805
Marshall VR *See* Grover PK et al 149
Martin D *See* Reyes AA et al 403
Martin J *See* Davies M et al 671
Martin LL *See* Smith SR et al 199
Martinelli D (abst) 1443
Marumo F *See* Sakamoto H et al 350
Maruyama Y *See* Hayashi H et al 749
Marx M *See* Madri JA et al 560
Mascher G (abst) 506
Mäser E (abst) 479
Mason PJ (abst) 704
Massara C (abst) 1439
Massry SG *See* Chervu I et al 1501
Masud T *See* May RC et al 1535
Matas AJ *See* Cheung AHS et al 924
Mathiesen ER *See* Borch-Johnsen K et al 719
Mauer M, Mogensen CE, Viberti GC: Introduction 717
Mauer SM, Sutherland DER, Steffes MW: Relationship of systemic blood pressure to nephropathology in insulin-dependent diabetes mellitus 736
Mauer SM *See* Lane PH et al 1085

Mauer SM *See* Vernier RL et al 1070
Mavromatidis K *See* Magoula I et al 1349
May RC, Masud T, Logue B, Bailey J, England B: Chronic metabolic acidosis accelerates whole body proteolysis and leucine oxidation in awake rats 1535
Mayfield RK *See* Jaffa AA et al 789
Mazzucco G (abst) 1447
Mazzuchi N *See* Fernández JM et al 1029
McCann WP *See* Barfuss DW et al 1143
McCulloch L (abst) 701
McCune BK *See* Roberts AB et al 557
McDonald J *See* Barrett BJ et al 1274
McFarland H *See* Choyke PL et al 1595
McHugh LE *See* Cheung AHS et al 924
McIntyre SJ *See* Rassier ME et al 88
McKay N (abst) 706
McKay NG (abst) 703
McKinley MJ: Common aspects of the cerebral regulation of thirst and renal sodium excretion 37:S-102
McLachlan EM, Luff SE: Sympathetic innervation of renal and extra-renal arterial vessels 37:S-56
McLeod AM (abst) 699
McManamon PJ *See* Barrett BJ et al 1274
McNurlan MA *See* Ballmer PE et al 132
Medina J (abst) 698
Mehlsen J (abst) 505, 506
Menè P (abst) 1442
Menè P, Pugliese F, D'Agostino A, Cinotti GA: Thromboxane A_2, prostaglandins, and mesangial cell proliferation 554
Mento PF *See* Wilkes BM et al 992
Merlino C (abst) 1439
Merriweather C (abst) 490
Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: A twenty-three year follow-up study 836
Messineo L (abst) 1443
Metsärinne K (abst) 499
Meyer X (abst) 490
Meyer-Lehnert H *See* Kramer HJ et al 36:S-2
Meyers C *See* Heeger P et al 220
Meyrier A *See* Mal F et al 445
Michael A (abst) 704
Michael AF *See* Kleppel MM et al 1629
Michel J-B *See* Anidjar S et al 37:S-61
Michinaga I *See* Ogahara S et al 175
Middleton JP *See* Collins DM et al 1292
Miettinen A (abst) 696
Mihatsch MJ (abst) 483, 491, 495, 1445
Milan M *See* Ronco C et al 1383
Miller D *See* Nakamura T et al 1213
Miller LG *See* Choyke PL et al 1595
Miller TE, Findon G, Rainer SP, Gavin JB: The pathology of subclinical pyelonephritis—An experimental evaluation 1356
Mimran A, Ribstein J, Jover B: Aging and sodium homeostasis 37:S-107
Mimura N *See* Ohashi K et al 1646
Min L (abst) 697
Min MG (abst) 1453
Minson J *See* Arnolda L et al 37:S-2
Minuth WW, Dermietzel R, Kloth S, Hennerkes B: A new method culturing renal cells under permanent superfusion and producing a luminal-basal medium gradient (Technical Note) 215
Minutolo R (abst) 1445
Mion CM *See* Kerr PG et al 1035
Mir S (abst) 1467, 1468, 1471
Mitchell KD *See* Carmines PK et al 36:S-43
Mittermair C (abst) 698
Miura AB *See* Komatsuda A et al 1204
Mjörnstedt L (abst) 509
Mocan H (abst) 1471
Mocciaro A (abst) 1439
Mogensen CE *See* Damsgaard EM et al 731
Mogensen CE *See* Hansen KW et al 847
Mogensen CE *See* Mauer M et al 717
Mogensen CE *See* Pederson MM et al 883
Mohaupt M *See* Kramer HJ et al 36:S-2
Molenaar JC (abst) 1437
Molitoris BA: The potential role of ischemia in renal disease progression 36:S-21
Moliz M (abst) 695
Moll R (abst) 489
Monga G (abst) 1447
Monnens LAH (abst) 1430
Montanari A (abst) 1445
Moon C (abst) 1458, 1459, 1459
Moon CO (abst) 1450, 1450, 1451, 1457, 1463
Moon DH (abst) 1450
Moon HR (abst) 1461
Moore KP, Taylor GW, Gove C, Wood J, Tan K-C, Eason J, Williams R: Synthesis and metabolism of the cysteinyl leukotrienes by the isolated pig kidney 1543
Morabito N (abst) 1444
More IAR *See* Gibson IW et al 211
Morgan TO, Anderson A: Hemodynamic comparisons of enalapril and felodipine and their combination 36:S-78
Morganti A (abst) 1446
Moriero E (abst) 1443
Morigi M (abst) 697
Morii H *See* Shoji T et al 1653
Morioka T (abst) 697
Mørkrid L *See* Ofstad J et al 36:S-8
Moromisato R *See* Nayak RC et al 1638
Morozumi K (abst) 1445
Morrissey J *See* Yanagisawa H et al 1000
Morton JJ *See* Lever AF et al 37:S-51
Moscatelli P (abst) 1446
Mosconi L *See* Gaspari F et al 1081
Motz W (abst) 487
Moudry-Munns KC *See* Cheung AHS et al 924
Mukhtar A (abst) 703
Müller CA (abst) 489, 489
Müller GA (abst) 482, 489, 489, 495, 703
Muller GY, Zabaleta ME, Arminio A, Colmenares CJ, Capriles FI, Bianco NE, Machado IV: Risk factors for dialysis-associated hepatitis C in Venezuela 1055
Müller M (abst) 489
Muller S (abst) 495
Müller V (abst) 498
Müller-Ruchholtz W (abst) 488
Mullins J *See* Bachman S et al 24
Mullins JJ *See* Barrett GL et al 37:S-125
Mülsch A (abst) 697
Munaut C (abst) 700
Munck O (abst) 508
Mundel P (abst) 489
Muollo B *See* Fioretto P et al 813
Muthny FA (abst) 488

Mutti A *See* Khalil-Manesh F et al 1192
Myers BD *See* Scandling JD et al 840
Myers JC *See* Alvarez RJ et al 14
Nadasdy T *See* Neufeld TK et al 1222
Nafz B (abst) 490
Nagata M *See* Sakai T et al 533
Nahas AME: Growth factors and glomerular sclerosis 36:S-15
Nahman NS Jr., Leonhart KL, Cosio FG, Hebert CL: Effects of high glucose on cellular proliferation and fibronectin production by cultured human mesangial cells 396
Naito S *See* Ogahara S et al 175
Najarian JS *See* Cheung AHS et al 924
Nakada J *See* Nosaka K et al 73
Nakamoto Y *See* Komatsuda A et al 1204
Nakamura T, Miller D, Ruoslahti E, Border WA: Production of extracellular matrix by glomerular epithelial cells is regulated by transforming growth factor-β1 1213
Nakamura Y *See* Sakamoto H et al 350
Nakazato Y *See* Sedor JR et al 595
Nankivell BJ, Fawdry RM, Harris DCH: Assessment of glomerular filtration rate in small animals by intraperitoneal ^{99m}Tc DTPA (Technical Note) 450
Napodano P (abst) 1447, 1447
Narita I (abst) 697
Nasini MG (abst) 1441
Nässberger L (abst) 507
Nast CC (abst) 700, 705
Nast CC *See* Ihm C-G et al 768
Natochin Y (abst) 478
Navar LG *See* Carmines PK et al 36:S-43
Nayak RC, Attawia MA, Cahill CJ, King GL, Ohashi H, Moromisato R: Expression of a monoclonal antibody (3G5) defined ganglioside antigen in the renal cortex 1638
Neild GH (abst) 695
Neilson EG *See* Alvarez RJ et al 14
Neilson EG *See* Heeger P et al 220
Neufeld TK, Douglass D, Grant M, Ye M, Silva F, Nadasdy T, Grantham JJ: In vitro formation and expansion of cysts derived from human renal cortex epithelial cells 1222
Neumayer H-H, Kunzendorf U, Schreiber M: Protective effects of calcium antagonists in human renal transplantation 36:S-87
Neusser M (abst) 495
Newman GE *See* Collins DM et al 1292
Ng LL, Davies JE: Lipids and cellular Na^+/H^+ antiport activity in diabetic nephropathy 872
Nicolosi G *See* Trevisan R et al 855
Niederreither K (abst) 706
Nielsen B (abst) 505, 506
Nielsen B *See* Parving H-H et al 758
Nielsen EM (abst) 511
Nielsen F (abst) 506
Nielsen PK (abst) 501, 502, 509
Nielsen SL (abst) 505
Nihei H *See* Ohashi K et al 1646
Niimi K *See* Santos F et al 356
Nishi S *See* Hayashi H et al 749
Nishitani H *See* Shoji T et al 1653
Nishizawa Y *See* Shoji T et al 1653
Nobiling R (abst) 479, 696
Nobiling R *See* Sakai T et al 533
Noble NA *See* Border WA et al 566
Nogués X *See* Sentí M et al 1394
Noh JW (abst) 1452, 1452
Noland TD *See* Takeda M et al 1713
Norby A (abst) 500
Nord CE (abst) 503
Nordal KP (abst) 500, 509
Nordén G (abst) 509
Nordlander M, Havu N: Effects of chronic felodipine treatment on renal function and morphology in SHR 36:S-100
Nordlander M *See* DiBona GF et al 36:S-1
Nordlander M *See* Elmfeldt D et al 36:S-54
Nørgaard K *See* Borch-Johnsen K et al 719
Noronha IL (abst) 480, 490, 497, 700
Nosadini R *See* Fioretto P et al 813
Nosadini R *See* Trevisan R et al 855
Nosaka K, Nakada J, Endou H: Cisplatin-induced alterations in renal structure, ammoniagenesis and gluconeogenesis of rats 73
Nouwen EJ (abst) 1435
Novarini A (abst) 1445
Nussenblatt R *See* Choyke PL et al 1595
Nutting CW, Islam S, Ye M, Batlle DC, Daugirdas JT: The vasorelaxant effects of acetate: Role of adenosine, glycolysis, lyotropism, and pH_i and Ca_i^{2+} 166
Nyberg G (abst) 509, 703
Nyländen P (abst) 508
Nystrand R (abst) 501
Oberle G (abst) 495
Oberleithner H (abst) 497
Obrant K (abst) 507
O'Brien RC *See* Cooper ME et al 898
Öcal G (abst) 1471
O'Dea F *See* Barrett BJ et al 1274
O'Donoghue DJ *See* Brenchley PE et al 933
Oe LP *See* Kouw PM et al 440
Oe PL (abst) 1438
Oehring H (abst) 482
Oemar BS (abst) 697
O'Farrell SC *See* Heeger P et al 220
Ofstad J, Horvei G, Kvam FI, Mørkrid L, Sekse I, Svarstad E, Iversen BM: Glomerular hemodynamics in progressive renal disease 36:S-8
Ogahara S, Naito S, Abe K, Michinaga I, Arakawa K: Analysis of HLA class II genes in Japanese patients with idiopathic membranous glomerulonephritis 175
Ogilvie A (abst) 490, 698
Ogino S *See* Hayashi H et al 749
Ogura Y *See* Ohashi K et al 1646
Oh DJ (abst) 1455, 1455
Oh HY (abst) 1450, 1452
Oh MS (abst) 1450
Ohashi H *See* Nayak RC et al 1638
Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H, Mimura N: Cervical discs are most susceptible to beta^2-microglobulin amyloid deposition in the vertebral column 1646
Oite T (abst) 697
Oko A (abst) 488
Ökten A (abst) 1471
Olausson M (abst) 509
Olbricht CJ, Geissinger B, Gutjahr E: Renal hypertrophy in streptozotocin diabetic rats: Role of proteolytic lysosomal enzymes 966
Ølgaard K (abst) 501, 501, 502, 508, 509, 512

Olgemöller B (abst) 705
Olivieri O (abst) 1446
Oliviero P *See* Beuve CS et al 37:S-45
Olthof CG *See* Kouw PM et al 440
Omboni S *See* Parati G et al 37:S-24
Onat O (abst) 1469
O'Neil LAJ: How does interleukin-1 activate cells? 546
Önen K (abst) 1466, 1466, 1467
Oozma G (abst) 1472
Opocher G *See* Fioretto P et al 813
Oreopoulos DG *See* Breborowicz A et al 1280
Ørskov H *See* Flyvbjerg A et al 805
Orzincolo C (abst) 1441
Osborne-Pellegrin M *See* Anidjar S et al 37:S-61
Østerby R (abst) 703
Østerby R *See* Walker JD et al 741
Östman A *See* Heldin C-H et al 571
Ostrow E *See* Tilton RG et al 778
Öttl I (abst) 496
Oudar O *See* Shahedi M et al 455
Owens DR *See* Vora JP et al 829
Öz H (abst) 1467
Özalp A (abst) 1471
Özcebe O (abst) 1470, 1471, 1472
Özdamar K (abst) 1467
Özdemir O (abst) 1470, 1471, 1472
Ozdemir Y (abst) 1469
Özdoğan E (abst) 1466, 1473
Özener Ç (abst) 1470
Özgözükara A (abst) 1467
Özgün S (abst) 1470
Paape ME (abst) 1431
Padalino PK *See* Koenig KG et al 161
Padovese P (abst) 1443
Pai KS (abst) 1453
Paillard M *See* Houillier P et al 1182
Palazzi P (abst) 1439
Pallone TL, Hyver SW, Petersen J: A model of the volumetrically-controlled hemodialysis circuit 1366
Pals SL (abst) 1438
Pancham R (abst) 1431
Panitz H (abst) 488
Panzetta G (abst) 1446
Paoletti E (abst) 1443
Paolini F (abst) 1446
Parati G, Omboni S, Di Rienzo M, Frattola A, Albini F, Mancia G: Twenty-four hour blood pressure variability: clinical implications 37:S-24
Parenti M (abst) 1439
Parfrey PS *See* Barrett BJ et al 1274
Park CG (abst) 1450
Park C-H (abst) 1448, 1449, 1460, 1460
Park CJ (abst) 1460
Park CS (abst) 1455
Park CW (abst) 1460
Park HC (abst) 1449, 1460, 1465
Park I (abst) 1463
Park IS (abst) 1448, 1455, 1464, 1464, 1465
Park JK (abst) 702, 1452, 1462
Park JS (abst) 1450, 1458
Park KK (abst) 1453
Park MCH (abst) 1465
Park MH (abst) 1452
Park MI (abst) 1457
Park MS (abst) 1458, 1459, 1459
Park SB (abst) 1453, 1458, 1460
Park SE (abst) 1457, 1461, 1461
Park SH (abst) 1464
Park SJ (abst) 1457
Park S-K (abst) 1448, 1450, 1458
Park Y-H (abst) 1460, 1465
Park YS (abst) 1451, 1451, 1451
Parks JH *See* Coe FL et al 139
Parlongo S (abst) 1442, 1443
Parving H-H, Gall M-A, Skøtt P, Jørgensen HE, Løkkegaard H, Jørgensen F, Nielsen B, Larsen S: Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients 758
Parving H-H *See* Borch-Johnsen K et al 719
Patrono C *See* Remuzzi G et al 1483
Paul M (abst) 496
Pavenstädt H (abst) 698
Pedersen E (abst) 505, 508, 508
Pedersen EB, Sørensen SS, Eiskjær H, Skovbon H, Thomsen K: Interaction between cyclosporine and felodipine in renal transplant patients 36:S-82
Pedersen RS (abst) 510
Pederson MM, Hansen KW, Schmitz A, Sørensen K, Christensen CK, Mogensen CE: Effects of ACE inhibition supplementary to beta blockers and diuretics in early diabetic nephropathy 883
Pederson MM *See* Hansen KW et al 847
Pedro-Botet J *See* Sentí M et al 1394
Pedrotti A, Bonjour J-P, Guignard J-P: Protection from hypoxemia-induced renal dysfunction by the thiophosphate WR-2721 80
Pehrsson SK (abst) 504
Pei Y, Hercz G, Greenwood C, Sherrard D, Segre G, Manuel A, Saiphoo C, Fenton S: Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients 1374
Pelegrí A *See* Sentí M et al 1394
Peltenburg HG *See* Kooman JP et al 1041
Penninckx R *See* Soupart A et al 1662
Perfumo F *See* Canepa A et al 1016
Perico N *See* Gaspari F et al 1081
Perier O *See* Soupart A et al 1662
Perinotto P (abst) 1445
Perrone RD: Means of clinical evaluation of renal disease progression 36:S-26
Persson B *See* Rudberg S et al 822
Persson I-B (abst) 512
Persson PB (abst) 481, 490
Peters J *See* Bachman S et al 24
Peters JR *See* Vora JP et al 829
Petersen J *See* Pallone TL et al 1366
Petersen K (abst) 486
Petrarulo M (abst) 1445
Petrini C (abst) 1445
Petruccelli D *See* Fernández JM et al 1029
Pettersson E (abst) 504
Pfaller K (abst) 497
Pfaller W (abst) 497
Pfeiffer C (abst) 705
Pfeilschifter J (abst) 490, 491, 697
Phan SH (abst) 1452
Philippe C *See* Baud L et al 600
Piazza V (abst) 1443
Picardi L (abst) 1443
Piccoli G (abst) 1442, 1442
Pilowsky P *See* Arnolda L et al 37:S-2
Pinerolo C (abst) 697

Pinto J *See* Jones SL et al 1620
Pippin J *See* Reyes AA et al 100
Pisetsky DS *See* Spurney RF et al 973
Pizzonia JH (abst) 485
Poggio F (abst) 1443
Poletti LF *See* Santos F et al 356
Ponticelli C (abst) 1446
Pontoriero G (abst) 1444
Pooth U (abst) 483
Porri MT (abst) 1447, 1447
Post M (abst) 701
Postma CT (abst) 1436
Postorino M (abst) 1443
Pouyssegur J (abst) 485
Povlsen JV (abst) 506, 509
Power DA (abst) 699, 703, 703, 706
Power DA *See* Ballmer PE et al 132
Pozzi C (abst) 1442
Preisig R *See* Schaad HJ et al 420
Prigent A *See* Houillier P et al 1182
Prins F (abst) 700
Pritzl P (abst) 701
Pritzl P *See* Floege J et al 297
Privitera M (abst) 1444
Proctor RK *See* Collins DM et al 1292
Provoost AP (abst) 1437
Prütz K (abst) 506
Pugliese F (abst) 1442
Pugliese F *See* Menè P et al 554
Pugliese G *See* Ido Y et al 435
Pusey CD (abst) 704
Pusey CD *See* Spencer SJW et al 1059
Pussard E *See* Berdeaux A et al 37:S-29
Pyun K-H (abst) 1453
Quamme GA: Free cadmium activity in renal epithelial cells is enhanced by Mg2+ depletion 1237
Quan ZY, Walser M, Hill GS: Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level 326
Quarello F (abst) 1442
Quarto Di Palo F (abst) 1439
Quednau B (abst) 494
Raasveld MHM (abst) 1438
Raatz SK *See* Salahudeen AK et al 183
Rabbia C (abst) 1439
Rabelink AJ (abst) 1436
Radeke HH (abst) 698
Radermacher J, Klanke B, Schurek H-J, Stolte HF, Frölich JC: Importance of NO/EDRF for glomerular and tubular function: Studies in the isolated perfused rat kidney 1549
Radice A (abst) 1442
Radounikli A (abst) 491
Raffelsiefer A (abst) 478
Rafftery M *See* Walker JD et al 741
Raghunath M (abst) 489
Ragni G (abst) 1445
Ragunath M (abst) 483
Rahilly MA (abst) 701
Rahn KH (abst) 478, 493, 495
Raij L *See* Tolins JP et al 1254
Rainer SP *See* Miller TE et al 1356
Rakhit A *See* Smith SR et al 199
Rambausek M (abst) 497, 498
Ramboer I, Blin P, Lacape G, Daret D, Lamaziere J-MD, Larrue J: Effects of monohydroxylated fatty acids on arterial smooth muscle cell properties 37:S-67
Ramirez G, Saba SR, Dietz JR, Vesely DL: Immunocytochemical localization of proANF 1-30, proANF 31-67, and atrial natriuretic factor in the kidney 334
Rannou F *See* Beuve CS et al 37:S-45
Rasmussen HH (abst) 511
Rasmussen K (abst) 502, 508, 508, 509
Rasmussen KC (abst) 508
Rasmussen LS (abst) 502
Rassier ME, McIntyre SJ, Yamaki M, Takeda S, Lin J-T, Dousa TP: Isozymes of cyclic-3′, 5′-nucleotide phosphodiesterases in renal epithelial LLC-PK_1 cells 88
Ratcliffe PJ (abst) 481
Ratcliffe PJ *See* Tan CC et al 1581
Rauterberg EW (abst) 492
Reboucas NA (abst) 485
Reddy R *See* Barrett BJ et al 1274
Redlak M (abst) 494
Rees AJ (abst) 704
Rees AJ *See* Spencer SJW et al 1059
Reichel H (abst) 491
Reilly RR (abst) 485
Rekola S (abst) 511, 511
Relander A (abst) 505
Remuzzi A (abst) 697
Remuzzi G (abst) 697
Remuzzi G, FitzGerald GA, Patrono C: Thromboxane synthesis and action within the kidney (Editorial Review) 1483
Remuzzi G *See* Fioretto P et al 813
Remuzzi G *See* Gaspari F et al 1081
Renner EL *See* Schaad HJ et al 420
Rennke HG *See* Anderson S et al 891
Repp H (abst) 486, 487
Resch K (abst) 698
Resnick L *See* Green DF et al 956
Ressem L (abst) 500
Reyes AA, Lefkowith J, Pippin J, Klahr S: Role of the 5-lipooxygenase pathway in obstructive nephropathy 100
Reyes AA, Martin D, Settle S, Klahr S: EDRF role in renal function and blood pressure of normal rats and rats with obstructive uropathy 403
Rha SY (abst) 1456
Rhee SK (abst) 1448, 1451
Ribstein J *See* Mimran A et al 37:S-107
Riedel E (abst) 494
Riehl J (abst) 493
Riesco A (abst) 695
Rifici V *See* Gupta S et al 1161
Ringoir S *See* Vanholder R et al 1707
Rippe B *See* Haraldsson BS et al 310
Risler T (abst) 489, 495
Risler T *See* Erley CM et al 1297
Ritz E (abst) 478, 479, 485, 486, 488, 491, 496, 496, 496, 497, 498
Rivolta R (abst) 1439
Rizza V (abst) 1445
Rob PM (abst) 491
Roberts AB, McCune BK, Sporn MB: TGF-β: Regulation of extracellular matrix 557
Robertz-Vaupel C-M (abst) 480
Robey PG *See* Kopp JB et al 56

Robinson RR: From the President: The International Society of Nephrology and Its Congresses 930
Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGFβ gene expression and bioactivity in proximal tubule 107
Rodela H *See* Breborowicz A et al 1280
Rodemann HP (abst) 482, 702, 703
Rodemann HP *See* Wolthuis A et al 124
Rodriguez-Puyol D (abst) 698
Rodriguez-Puyol M (abst) 698
Roggendorf M (abst) 483
Roh JW (abst) 1450
Rolla D (abst) 1443
Romano U (abst) 1445
Rombolà G (abst) 1441
Romero J (abst) 491
Romero R *See* Sentí M et al 1394
Ronco C, Brendolan A, Feriani M, Milan M, Conz P, Lupi A, Berto P, Bettini MC, Greca GL: A new scintigraphic method to characterize ultrafiltration in hollow fiber dialyzers 1383
Ronco P *See* Stefanovič V et al 1571
Rootwelt K (abst) 500
Rosen VJ *See* Khalil-Manesh F et al 1192
Rosenberg ME *See* Correa-Rotter R et al 796
Rosenberg ME *See* Correa-Rotter R et al 938
Rosenberg ME *See* Salahudeen AK et al 183
Rosenlöf K (abst) 499
Rosenzweig SA (abst) 697
Rossi M (abst) 1446
Rössner S (abst) 503
Rother K (abst) 496
Rothlein R, Wegner C: Role of intercellular adhesion molecule-1 in the inflammatory response 617
Rotunno M (abst) 1439
Rouch AJ, Whitford GM, Campbell HT: Fluoride flux in the rabbit CCD: A pH-dependent event 342
Roy-Chaudhury P (abst) 699
Roy-Chaudhury P *See* Ballmer PE et al 132
Rubiés-Prat J *See* Sentí M et al 1394
Rudberg S, Persson B, Dahlquist G: Increased glomerular filtration rate as a predictor of diabetic nephropathy—An 8-year prospective study 822
Ruef C *See* Coleman DL et al 604
Ruffet M *See* Charra B et al 1286
Ruggenenti P *See* Gaspari F et al 1081
Ruiz P *See* Spurney RF et al 973
Rumble JR *See* Cooper ME et al 898
Rump LC (abst) 491
Ruoslahti E *See* Nakamura T et al 1213
Rupprecht HD (abst) 698
Russo D (abst) 1445
Russo R (abst) 1446
Ryall RL *See* Grover PK et al 149
Ryan US *See* Green DF et al 1506
Rybczyńska A (abst) 492
Saatçi Ü (abst) 1470, 1470
Saba SR *See* Ramirez G et al 334
Sabadini E (abst) 1445, 1447, 1447
Sachs C *See* Shahedi M et al 455
Sadler R *See* Bakris GL et al 912
Sağlamer L (abst) 1467
Said R, Hamzeh Y, Said S, Tarawneh M, Al-Khateeb M: Spectrum of renal involvement in familial Mediterranean fever 414
Said S *See* Said R et al 414
Sainio K (abst) 696
Saiphoo C *See* Pei Y et al 1374
Saitou T *See* Hayashi H et al 749
Sakai T, Lemley KV, Hackenthal E, Nagata M, Nobiling R, Kriz W: Changes in glomerular structure following acute mesangial failure in the isolated perfused kidney 533
Sakamoto H, Sasaki S, Nakamura Y, Fushimi K, Marumo F: Regulation of endothelin-1 production in cultured rat mesangial cells 350
Sala MR (abst) 1446
Salahudeen AK, Hostetter TH, Raatz SK, Rosenberg ME: Effects of dietary protein in patients with chronic renal transplant rejection 183
Salít M (abst) 1441
Salmonson T (abst) 500, 504, 504
Salnitro F (abst) 1444
Salvadeo A (abst) 1443
Samuelsson O (abst) 499
San A (abst) 1472, 1473
Sandberg SM *See* Ciresi DL et al 1599
Sandgren H (abst) 506
Sandhagen B (abst) 506
Sandrini S (abst) 1440, 1440
Sandstrom DJ *See* Anderson S et al 891
Sandvik L *See* Dahl-Jørgensen K et al 920
Sanfilippo F *See* Spurney RF et al 973
Sanna G (abst) 1447
Santoro A (abst) 1446
Santos F, Chan JCM, Krieg RJ, Niimi K, Hanna JD, Wellons MD, Poletti LF: Growth hormone secretion from the pituitary cells in chronic renal insufficiency 356
Sardet C (abst) 485
Sariyar M (abst) 1466
Sarsmaz N (abst) 1467
Sasaki S *See* Sakamoto H et al 350
Sassard J *See* Barrès C et al 37:S-19
Savill J (abst) 704
Savill J: Apoptosis: A mechanism for regulation of the cell complement of inflamed glomeruli 607
Savolainen MJ *See* Hörkkö S et al 1175
Sawada S *See* Lemoine R et al 65
Scaini P (abst) 1440, 1440
Scandling JD, Myers BD: Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease 840
Schaad HJ, Frey BM, Renner EL, Preisig R, Frey FJ: Microsomal liver function declines steadily after kidney grafting: A three to five year follow-up 420
Schaefer RM (abst) 704
Schafer JA, Hawk CT: Regulation of Na^+ channels in the cortical collecting duct by AVP and mineralocorticoids (Editorial Review) 255
Schaffer AV *See* Smith SR et al 199
Schalekamp MADH (abst) 1437
Schalkwijk J (abst) 1430
Schambelan M *See* Al-Uzri A et al 1701
Schellenberg A (abst) 492
Scherberich JE (abst) 479, 488, 492, 492, 498
Scherberlch J (abst) 486
Scheuermann E (abst) 479, 498
Scheyerl F (abst) 495, 495
Schild C (abst) 481
Schimpf BA *See* Zager RA et al 1588
Schindler R (abst) 481, 698

Schirop T (abst) 486
Schleicher E (abst) 705
Schlipköter U (abst) 483
Schlondorff D *See* Gupta S et al 1161
Schlondorff D *See* Wilkes BM et al 992
Schlottmann K (abst) 492
Schlüter H (abst) 493
Schmiedeke T (abst) 495
Schmitt H (abst) 483, 493
Schmitz A *See* Pederson MM et al 883
Schmouder RL, Strieter RM, Wiggins RC, Chensue SW, Kunkel SL: In vitro and in vivo interleukin-8 production in human renal cortical epithelia 191
Schneider H *See* Kouw PM et al 440
Schneider M (abst) 488
Schoeppe W (abst) 479, 483, 483, 491, 492, 492, 495, 497, 498, 696
Schollmeyer P (abst) 489, 491, 698
Schollmeyer PJ (abst) 479
Scholz H (abst) 493
Schöngen N (abst) 493
Schoots AC (abst) 1433
Schrama E (abst) 1432
Schrama YC (abst) 1433
Schramek H (abst) 497
Schreiber A (abst) 491
Schreiber M *See* Neumayer H-H et al 36:S-87
Schreiner GF *See* Takahashi K et al 1245
Schrier RW (abst) 699
Schrier RW *See* Almeida ARP et al 1494
Schrier RW *See* Hensen J et al 1333
Schröder K *See* Hensen J et al 1333
Schroijen VJHM (abst) 1432
Schubert I (abst) 492
Schulze-Lohoff E (abst) 490, 698
Schurek H-J *See* Radermacher J et al 1549
Schuster MJ (abst) 491
Schwaabe S (abst) 705
Schwab SJ *See* Collins DM et al 1292
Schwertfeger E (abst) 491
Schwietzer G (abst) 483, 497
Schwoerbel C (abst) 492
Scigalla P (abst) 496
Scolari F (abst) 1440, 1440
Sedor JR, Nakazato Y, Konieczkowski M: Interleukin-1 and the mesangial cell 595
Segagni S (abst) 1443
Segoloni GP (abst) 1439, 1439
Segre G *See* Pei Y et al 1374
Seifert RA *See* Floege J et al 297
Sekse I *See* Ofstad J et al 36:S-8
Selçuk Y (abst) 1473
Selvi A (abst) 1440
Semplicini A *See* Trevisan R et al 855
Sentí M, Romero R, Pedro-Botet J, Pelegrí A, Nogués X, Rubiés-Prat J: Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure 1394
Sepe V (abst) 1445
Sepe V *See* Canton AD et al 951
Serdengeçti K (abst) 1466, 1466
Serventi M (abst) 1445
Setenay Dinçer K (abst) 1467
Setti G (abst) 1440, 1440
Settle S *See* Reyes AA et al 403
Sever L (abst) 1467, 1467
Sever M (abst) 1471
Sever MŞ (abst) 1466, 1473
Sewing KF (abst) 487
Shahedi M, Laborde K, Lelongt B, Oudar O, Sachs C: A cytochemical procedure for determination of Na^+,K^+-ATPase activity in MDCK cells (Technical Note) 455
Shan Z *See* Gupta S et al 1161
Shanley PF *See* Ford DM et al 1606
Shapiro JI *See* Hiatt WR et al 1613
Sharma A (abst) 704
Shaw S (abst) 481, 493
Sherrard D *See* Pei Y et al 1374
Shibata T *See* Lemoine R et al 65
Shimada H *See* Lemoine R et al 65
Shimizu F (abst) 697
Shin HS (abst) 1459
Shin JH (abst) 1448
Shin SH (abst) 1448, 1451
Shin YT (abst) 1448, 1451
Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H: Impaired metabolism of high density lipoprotein in uremic patients 1653
Short CD *See* Brenchley PE et al 933
Sick H (abst) 484
Sicuso C (abst) 1442
Sidoti A (abst) 1445
Sieberth H-G (abst) 482, 483, 493
Sieberth H-G *See* Ittel TH et al 1340
Siegbahn A *See* Heldin C-H et al 571
Siems W (abst) 494
Siffert W (abst) 494
Silomon JF (abst) 483
Silva F *See* Neufeld TK et al 1222
Simon JM *See* Freyss-Beguin MM et al 37:S-79
Simon T *See* Choyke PL et al 1595
Simonsen O (abst) 504
Simonson MS, Jones JM, Dunn MJ: Cytosolic and nuclear signaling by endothelin peptides: Mesangial response to glomerular injury 542
Sinaz A (abst) 1472
Sindel S (abst) 1472
Singhal PC, Gibbons N, Abramovici M: Long term effects of morphine on mesangial cell proliferation and matrix synthesis 1560
Sinico RA (abst) 1442, 1447, 1447
Sisson-Ross S *See* Vernier RL et al 1070
Sixma JJ (abst) 1436
Sjögren B (abst) 510
Skaarup P (abst) 508
Skielbo M (abst) 505
Skielboe M (abst) 505
Skøtt P *See* Parving H-H et al 758
Skovbon H *See* Pedersen EB et al 36:S-82
Skrasting A (abst) 493
Skroch D (abst) 495
Slayman CW (abst) 485
Slikkerveer A (abst) 1432
Sluiter HE *See* Frenken LAM et al 384
Sluiter HE *See* Huysmans FTM et al 36:S-106
Sluiter HE *See* van Hamersvelt HW et al 36:S-73
Smet RD *See* Vanholder R et al 1707
Smith SR, Creech EA, Schaffer AV, Martin LL, Rakhit A, Douglas FL, Klotman PE, Coffman TM: Effects of thromboxane synthase inhibition with CGS 13080 in human cyclosporine nephrotoxicity 199

Smith SR *See* Tilton RG et al 778
Smits P (abst) 1436
Smogorzewski M *See* Chervu I et al 1501
Sohn SH (abst) 1453, 1456, 1458, 1458, 1459, 1463, 1463
Solbu D (abst) 507
Soleimani B *See* Esnault VLM et al 1304
Soliani F (abst) 1441
Son HS (abst) 1454
Sone M (abst) 494
Song JS (abst) 1455, 1455
Sönmez G (abst) 1472
Sonsuz A (abst) 1466
Sørensen JP (abst) 502
Sørensen K *See* Pederson MM et al 883
Sørensen SS *See* Pedersen EB et al 36:S-82
Sorokin L, Ekblom P: Development of tubular and glomerular cells of the kidney 657
Soupart A, Penninckx R, Stenuit A, Perier O, Decaux G: Treatment of chronic hyponatremia in rats by intravenous saline: Comparison of rate versus magnitude of correction 1662
Söylemezoğlu O (abst) 1470, 1470
Späth M (abst) 698
Spencer SJW, Burns A, Gaskin G, Pusey CD, Rees AJ: HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens 1059
Spongano M (abst) 1446
Sporn MB *See* Roberts AB et al 557
Spring J (abst) 701
Spurney RF, Fan P-Y, Ruiz P, Sanfilippo F, Pisetsky DS, Coffman TM: Thromboxane receptor blockade reduces renal injury in murine lupus nephritis 973
Sredni B *See* Gafter U et al 143
Stahl RAK (abst) 483, 483, 491, 495, 696
Steen Olsen T (abst) 499, 508
Stefani A (abst) 1441
Stefanovič V, Vlahovič P, Ardaillou N, Ronco P, Ardaillou R: Cell surface aminopeptidase A and N activities in human glomerular epithelial cells 1571
Steffensen G (abst) 506
Steffes MW *See* Lane PH et al 1085
Steffes MW *See* Mauer SM et al 736
Steffes MW *See* Vernier RL et al 1070
Steffgen J (abst) 494, 495, 495
Stegeman CA (abst) 1435
Stegmayr B (abst) 502, 506
Stehouwer CDA (abst) 1433
Stein G (abst) 482
Steinhauer HB (abst) 489
Steinhausen M (abst) 492
Stentoft J (abst) 511
Stenuit A *See* Soupart A et al 1662
Stenver D (abst) 505, 506
Stenvinkel P (abst) 503
Sterzel RB (abst) 490, 698, 698
Sterzel RB *See* Kashgarian M et al 524
Sterzel RB *See* Madri JA et al 523
Stöckl F (abst) 495
Stolte HF *See* Radermacher J et al 1549
Stone BG *See* Tolins JP et al 1254
Stone E *See* Barrett BJ et al 1274
Störkel S (abst) 492
Storm T (abst) 503
Strandgaard S (abst) 499, 508
Strate M (abst) 510
Stratta P (abst) 1447
Strauer BE (abst) 487
Streefland C (abst) 1437
Streekstra G (abst) 1436
Strieter RM (abst) 695
Strieter RM *See* Schmouder RL et al 191
Strömbom U (abst) 511
Stroomer MKJ (abst) 1437
Struijk DG (abst) 1436
Struijk DG, Koomen GCM, Krediet RT, Arisz L: Indirect measurement of lymphatic absorption in CAPD patients is not influenced by trapping 1668
Strutz F (abst) 495
Struyker-Boudier HAJ *See* Kooman JP et al 1041
Sucak G (abst) 1472
Sudhir K *See* Angus JA et al 37:S-73
Suk CW (abst) 1456
Sukhatme VP (abst) 698
Sukhatme VP: The Egr transcription factor family: From signal transduction to kidney differentiation 550
Şükrü Sever M (abst) 1467
Sun MJ *See* Alvarez RJ et al 14
Sun MJ *See* Heeger P et al 220
Sun X (abst) 1438
Sung KH (abst) 1449, 1460, 1465
Sung KT (abst) 1449
Sungur C (abst) 1469, 1471, 1472
Sutherland DER *See* Cheung AHS et al 924
Sutherland DER *See* Mauer SM et al 736
Suzuki Y *See* Hayashi H et al 749
Svaland M (abst) 500
Svalander C (abst) 511
Svarstad E *See* Ofstad J et al 36:S-8
Swynghedauw B *See* Beuve CS et al 37:S-45
Symreng T, Flanigan MJ, Lim VS: Ventilatory and metabolic changes during high efficiency hemodialysis 1064
Szczepańska-Konkel M (abst) 494
Szewczyk Z (abst) 487
Takahashi K, Kato T, Schreiner GF, Ebert J, Badr KF: Essential fatty acid deficiency normalizes function and histology in rat nephrotoxic nephritis 1245
Takeda M, Breyer MD, Noland TD, Homma T, Hoover RL, Inagami T, Kon V, Fredin DM, Hellings SE: Endothelin-1 receptor antagonist: Effects on endothelin- and cyclosporine-treated mesangial cells 1713
Takeda S *See* Rassier ME et al 88
Tamsma JT (abst) 1432
Tan CC (abst) 481
Tan CC, Ratcliffe PJ: Rapid oxygen-dependent changes in erythropoietin mRNA in perfused rat kidney: Evidence against mediation by cAMP 1581
Tan K-C *See* Moore KP et al 1543
Taranta A (abst) 1442
Tarantino A (abst) 1439
Tarawneh M *See* Said R et al 414
Tariq T *See* Lopes de Faria JB et al 877
Tarjan E, Denton DA, Ferraro T, Weisinger RS: Effect of CRF, ACTH and adrenal steroids on sodium intake and excretion of rabbits 37:S-97
Tarolo G (abst) 1443
Tasby J *See* Truong LD et al 1676
Tashima Y *See* Komatsuda A et al 1204
Taskinen E *See* Isoniemi HM et al 155
Tatlikazan L (abst) 1473
Tauber M (abst) 492
Taylor GW *See* Moore KP et al 1543

Telaferli A (abst) 1467
ten Berge RJM (abst) 1438
Tepel M (abst) 495
ter Wee PM *See* Kouw PM et al 440
Terkildsen K (abst) 511
Termine JD *See* Kopp JB et al 56
Terzloğlu O (abst) 1471
Teschner M (abst) 704
Tevfik Ecder S (abst) 1467
Thaiss F (abst) 483, 483, 491, 495, 696
Thea A (abst) 1447
Thiel G (abst) 498
Thiel G *See* Bock HA et al 275
Thien Th (abst) 1436
Thoenes W (abst) 489
Thomas D *See* Vora JP et al 829
Thomas GJ *See* Davies M et al 671
Thomsen K *See* Pedersen EB et al 36:S-82
Thurau K (abst) 494
Thysell H (abst) 511
Tiengo A *See* Fioretto P et al 813
Tilocca P (abst) 1447
Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR: Diabetes-induced glomerular dysfunction: Links to a more reduced cytosolic ratio of NADH/NAD$^+$ 778
Tilton RG *See* Ido Y et al 435
Timpka T (abst) 502
Tinaztepe K (abst) 1466
Tiselius H-G (abst) 510
Tizianello A (abst) 1446
Toback FG: Regeneration after acute tubular necrosis (Nephrology Forum) 226
Tolbert E *See* Lax DS et al 1527
Tolins JP, Stone BG, Raij L: Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury 1254
Tomiyama T (abst) 1431
Tomooka S *See* Border WA et al 566
Tonbul HZ (abst) 1472, 1473
Topaloğlu R (abst) 1470
Topley N (abst) 699
Törnroth T (abst) 508
Torrat J-C *See* Charra B et al 1286
Torre L *See* Gaspari F et al 1081
Travaglini M (abst) 481, 1443
Trevisan R, Nosadini R, Fioretto P, Semplicini A, Donadon V, Doria A, Nicolosi G, Zanuttini D, Cipollina MR, Lusiani L, Avogaro A, Crepaldi G, Viberti GC: Clustering of risk factors in hypertensive insulin-dependent diabetics with high sodium-lithium countertransport 855
Trevisan R *See* Fioretto P et al 813
Triolo G (abst) 1439
Troschau G (abst) 497
Troy JL *See* Anderson S et al 891
Truong LD, Farhood A, Tasby J, Gillum D: Experimental chronic renal ischemia morphologic and immunologic studies 1676
Tsai P (abst) 699
Tsalamandris C *See* Jerums G et al 904
Tsapas G *See* Magoula I et al 1349
Tschernko E (abst) 496
Tschope W (abst) 496
Tsobanelis T (abst) 496
Tufveson G (abst) 507
Tufvesson G (abst) 501
Tülbek MY (abst) 1468
Tümer N (abst) 1471
Tuna Ş (abst) 1466, 1473
Turgan Ç (abst) 1469, 1470, 1471, 1472
Turner N (abst) 704
Tvedt KE (abst) 500
Ucci AA *See* Vlahakos DV et al 1690
Ucmakli E (abst) 1468
Ueno M *See* Hayashi H et al 749
Ülkü U (abst) 1466, 1466
Ullrich KJ (abst) 478, 479, 480
Ulrichs K (abst) 488
Ulukutlu L (abst) 1467
Ünlübozkurt M (abst) 1467
Usadel K-H (abst) 486
Uslu S (abst) 1467
VaaBen W (abst) 482
Valpondi P (abst) 1441
van Acker BAC (abst) 1437, 1437
van Bommel EFH (abst) 1434
van Bortel L (abst) 1433
van Bortel LMAB (abst) 1434
van Bortel LMAB *See* Kooman JP et al 1041
van Buren M (abst) 1434
Van De Voorde J (abst) 1432
van de Wiel BA (abst) 1431
van den Born J (abst) 1432
van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann KJM, Berden JHM: A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats 115
van den Dobbelsteen MEA (abst) 695, 1435
van den Heuvel LPWJ *See* van den Born J et al 115
van den Ouweland AMW (abst) 1430
van der Horst MLC (abst) 1431
van der Hoven B (abst) 1434
van der Meulen J (abst) 1438
van der Wal A (abst) 1430
van der Woude FJ (abst) 695, 1431, 1435
van Diemen-Steenvoorde R (abst) 1430
van Diepen FNJ (abst) 1438
van Es LA (abst) 695, 1431, 1435
van Es LA: Pathogenesis of IgA nephropathy (Nephrology Forum) 1720
van Es PN (abst) 1436
van Gompel APM (abst) 1430
van Goor H (abst) 1431
van Hamersvelt HW, Sluiter HE, Wetzels JFM, Koene RAP, Huysmans FTM: Is natriuresis on felodipine due to reversal of the renal effects of angiotensin II? 36:S-73
van Hamersvelt HW *See* Huysmans FTM et al 36:S-106
van Hooff JP (abst) 1433, 1434, 1435
van Hooff JP *See* Kooman JP et al 1041
van Leengoed LAMG (abst) 1434
van Olden RW (abst) 1433
van Oost BA (abst) 1430
van Os CH (abst) 1434
van Rooyen N (abst) 1430
van Tol A (abst) 1438
van Willebrand E *See* Isoniemi HM et al 155
Vanel T *See* Charra B et al 1286

Vanholder R, Hoefliger N, Smet RD, Ringoir S, Vogeleere P: Extraction of protein bound ligands from azotemic sera: Comparison of 12 deproteinization methods (Technical Note) ... 1707
Vanuytsel J (abst) ... 1433
Vasilakakis DM, D'Haese PC, Lamberts LV, Lemoniatou E, Digenis PN, Broe MED: Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis ... 1400
Vavasour HM *See* Barrett BJ et al ... 1274
vd Born J (abst) ... 1432
vd Woude FJ (abst) ... 1432
Veerkamp JH *See* van den Born J et al ... 115
Vegeto A (abst) ... 1439
Vehaskari VM *See* Bonilla-Felix M et al ... 1150
Veis JH *See* Berl T et al ... 37
Verbeke M (abst) ... 1432
Vercellone A (abst) ... 1439, 1439, 1447
Vernier RL, Steffes MW, Sisson-Ross S, Mauer SM: Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus ... 1070
Verstrepen W (abst) ... 1435
Vesely DL *See* Ramirez G et al ... 334
Viberti G *See* Jones SL et al ... 1620
Viberti GC *See* Lopes de Faria JB et al ... 877
Viberti GC *See* Mauer M et al ... 717
Viberti GC *See* Messent JWC et al ... 836
Viberti GC *See* Trevisan R et al ... 855
Viberti GC *See* Walker JD et al ... 741
Viganò E (abst) ... 1446
Viganò G *See* Gaspari F et al ... 1081
Villa G (abst) ... 1443
Virotta G *See* Gaspari F et al ... 1081
Virtanen I *See* Korhonen M et al ... 641
Vitale C (abst) ... 1445
Vitulo F (abst) ... 1444
Vlahakos DV, Foster MH, Adams S, Katz M, Ucci AA, Barrett KJ, Datta SK, Madaio MP: Anti-DNA antibodies form immune deposits at distinct glomerular and vascular sites ... 1690
Vlahovič P *See* Stefanovič V et al ... 1571
Vogeleere P *See* Vanholder R et al ... 1707
Vogt A (abst) ... 495
Voisard R (abst) ... 483
Volkmann R (abst) ... 500, 512
von dem Borne AEGKr (abst) ... 1431
von der Mark H *See* von der Mark K et al ... 632
Von der Mark K (abst) ... 696
von der Mark K, von der Mark H, Goodman S: Cellular response to extracellular matrix ... 632
Vora JP, Dolben J, Dean JD, Thomas D, Williams JD, Owens DR, Peters JR: Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus ... 829
Vos PF (abst) ... 1435
Vosbeck K (abst) ... 697
Vrtovsnik F, El Yandouzi EH, Le Grimellec C, Friedlander G: Sphingomyelin and cholesterol modulate sodium coupled uptakes in proximal tubular cells ... 983
Waaga A-M (abst) ... 488
Wagner C (abst) ... 496
Wagner E (abst) ... 705
Wagner J (abst) ... 496, 496
Wahlberg J (abst) ... 501, 509
Wakai S, Magil AB: Focal glomerulosclerosis in idiopathic membranous glomerulonephritis ... 428
Wakui H *See* Komatsuda A et al ... 1204
Waldegger S (abst) ... 488
Waldherr R (abst) ... 480, 490, 497, 700, 701
Walker JD, Close CF, Jones SL, Rafftery M, Keen H, Viberti GC, Østerby R: Glomerular structure in type-1 (insulin-dependent) diabetic patients with normo- and microalbuminuria ... 741
Walser M *See* Quan ZY et al ... 326
Wandel E (abst) ... 487
Waniewski J *See* Heimburger O et al ... 1320
Wanner C (abst) ... 698
Wantzin P (abst) ... 502
Ward JE *See* Angus JA et al ... 37:S-73
Ward RA (abst) ... 482
Warram JH *See* Barzilay J et al ... 723
Wasewicz M (abst) ... 492
Watanabe Y, Kashihara N, Makino H, Kanwar YS: Modulation of glomerular proteoglycans by insulin-like growth factor-1 ... 1262
Waterloos M (abst) ... 1432
Watson H *See* Ballmer PE et al ... 132
Watson ML, Macnicol AH, Allan PL, Wright AF: Effects of angiotensin converting enzyme inhibition in adult polycysic kidney disease ... 206
Webb DR *See* Coe FL et al ... 139
Weber BK *See* Ballmer PE et al ... 132
Weber M: Basement membrane proteins ... 620
Weber RFA (abst) ... 1437
Weening JJ (abst) ... 702, 1432, 1432
Wegner C *See* Rothlein R et al ... 617
Wehrle-Haller B (abst) ... 701
Wehrmann M (abst) ... 484
Weidmann P (abst) ... 481, 493
Weidmann P *See* Blumberg A et al ... 369
Weier S (abst) ... 492
Weinlich M (abst) ... 1444
Weinreich T (abst) ... 479
Weis H (abst) ... 497
Weisberg LS, Kurnik PB, Kurnik BRC: Radiocontrast-induced nephropathy in humans: Role of renal vasoconstriction ... 1408
Weisinger RS *See* Tarjan E et al ... 37:S-97
Weiss H (abst) ... 488
Weiss L (abst) ... 506
Weisstuch JM, Dworkin LD: Does essential hypertension cause end-stage renal disease? ... 36:S-33
Welcer EH (abst) ... 699
Weller A (abst) ... 705
Wellons MD *See* Santos F et al ... 356
Wendel G (abst) ... 494
Wentzel T (abst) ... 506
Wenzel UO (abst) ... 497
Werle E (abst) ... 484
Werynski A *See* Heimburger O et al ... 1320
Wessén P (abst) ... 506
Westberg G (abst) ... 511
Westenfelder C (abst) ... 699
Westermark B *See* Heldin C-H et al ... 571
Westphale H-J (abst) ... 497
Westwick J (abst) ... 695
Wetzels JFM *See* Almeida ARP et al ... 1494
Wetzels JFM *See* Elving LD et al ... 862
Wetzels JFM *See* Frenken LAM et al ... 384
Wetzels JFM *See* Huysmans FTM et al ... 36:S-106
Wetzels JFM *See* van Hamersvelt HW et al ... 36:S-73
Wheeler DC (abst) ... 699
Whitford GM *See* Rouch AJ et al ... 342

Whitworth JA: Adrenocorticotrophin and steroid-induced hypertension in humans ... 37:S-34
Widerøe TE (abst) ... 507
Widstam-Attorps U (abst) ... 512
Więcel A (abst) ... 488
Wieslander J (abst) ... 511
Wiggins RC (abst) ... 1452, 1452
Wiggins RC *See* Schmouder RL et al ... 191
Wijnen JAG *See* Kooman JP et al ... 1041
Wikström B (abst) ... 501
Wikström B (abst) ... 500, 501, 504, 504, 506, 507, 509
Wiktröm B (abst) ... 512
Wilkes BM, Kaplan R, Mento PF, Aynedjian HS, Macica CM, Schlondorff D, Bank N: Reduced glomerular thromboxane receptor sites and vasoconstrictor responses in diabetic rats ... 992
Williams JD (abst) ... 699
Williams JD *See* Vora JP et al ... 829
Williams R *See* Moore KP et al ... 1543
Williamson JR *See* Ido Y et al ... 435
Williamson JR *See* Tilton RG et al ... 778
Willinger CC (abst) ... 497
Windus DW *See* Delmez JA et al ... 1023
Winkler D (abst) ... 481
Winther K (abst) ... 505, 506
Wirth S (abst) ... 481
Wirtz C (abst) ... 478
Wiseman M *See* Jones SL et al ... 1620
Wissmann C (abst) ... 486
Wolf G *See* Heeger P et al ... 220
Wöll E (abst) ... 488
Wolthuis A (abst) ... 702
Wolthuis A, Boes A, Rodemann HP, Grond J: Vasoactive agents affect growth and protein synthesis of cultured rat mesangial cells ... 124
Woo HJ (abst) ... 1455
Woo JY (abst) ... 1448, 1464, 1464
Wood J *See* Moore KP et al ... 1543
Woun KK (abst) ... 1456
Woytacha DR (abst) ... 699
Wrigge P (abst) ... 484
Wright AF *See* Watson ML et al ... 206
Wright CE *See* Angus JA et al ... 37:S-73
Wunderle W (abst) ... 484
Xiaosheng Y (abst) ... 1435
Yalçinkaya F (abst) ... 1471
Yamaç K (abst) ... 1472
Yamakawa M *See* Shoji T et al ... 1653
Yamaki M *See* Rassier ME et al ... 88
Yamamoto T *See* Border WA et al ... 566
Yamamoto T *See* Kawasaki K et al ... 1517
Yamaner S (abst) ... 1471
Yanagisawa H, Morrissey J, Yates J, Hayes C, Klahr S: Protein increases glomerular eicosanoid production and activity of related enzymes ... 1000
Yang CW (abst) ... 1455
Yang KH (abst) ... 1460
Yang SH (abst) ... 1457, 1461, 1461
Yang WS (abst) ... 1453
Yaoita E *See* Kawasaki K et al ... 1517
Yard BA (abst) ... 1431
Yasavųl Ü (abst) ... 1469, 1470, 1471, 1472
Yates J *See* Yanagisawa H et al ... 1000
Yavuz M (abst) ... 1466, 1468
Ye M *See* Neufeld TK et al ... 1222
Ye M *See* Nutting CW et al ... 166
Yergök YZ (abst) ... 1468
Yi GW (abst) ... 1448, 1451
Yi Y (abst) ... 1458
Yildiz I (abst) ... 1467
Yilmazlar T (abst) ... 1473
Ylänne J *See* Korhonen M et al ... 641
Yong HS (abst) ... 1456
Yoon J (abst) ... 1462
Yoon JB (abst) ... 1449, 1449
Yoon SA (abst) ... 1448, 1464
Yoon YS (abst) ... 1448, 1455, 1457, 1460, 1460, 1463, 1464, 1464, 1464, 1464, 1464, 1465
Yoshimura A *See* Floege J et al ... 297
Yoshimura A *See* Johnson R et al ... 590
Yoshioka T, Fogo A, Beckman JK: Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion ... 1008
Young MF *See* Kopp JB et al ... 56
Yu SH (abst) ... 1455, 1455
Yurtkuran M (abst) ... 1466, 1468
Zabaleta ME *See* Muller GY et al ... 1055
Zachariae H (abst) ... 508
Zager RA, Bredl CR, Schimpf BA: Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents ... 1588
Zahner G (abst) ... 483, 696
Zanner S (abst) ... 698
Zanussi C (abst) ... 1439
Zanuttini D *See* Trevisan R et al ... 855
Zaoui P *See* Himmelfarb J et al ... 388
Zayas MA *See* Anderson S et al ... 891
Zeh K (abst) ... 496
Zeier M (abst) ... 498
Zerwekh JE *See* Koenig KG et al ... 161
Zidek W (abst) ... 493, 495
Ziegler R (abst) ... 484
Zimmerman G (abst) ... 705
Ziyadeh FN *See* Rocco MV et al ... 107
Zoccali C (abst) ... 1442, 1443, 1444
Zoja C (abst) ... 697
Zucchelli P (abst) ... 1446
Zwaginga JJ (abst) ... 1436
Zweegman S (abst) ... 1438

Subject Index For Volume 41

Ablation
adrenalectomized rats ... 326
glomerular cell proliferation ... 297
intrarenal clusterin following ... 938
Acetate, vasorelaxant effects ... 166
Acid-base balance
intracellular proton buffering ... 43
potential, effect in calcium transport ... 289
vasorelaxant effect of acetate ... 166
in vitro intracellular recording (abst) ... 1444
Actin, muscle-specific ... 1134
Acute renal failure
cisplatin-induced ... 73
contrast media induced ... 1008
dialysis (abst) ... 510
felodipine ... 36:S-94
nitroprusside, urodilatin, dopamine (abst) ... 493
ovarian carcinoma (abst) ... 1468
postischemic distribution, neutrophils (abst) ... 497
rhabdomyolysis (abst) ... 1451
vascular access (abst) ... 501
Acute tubular necrosis, Nephrology Forum ... 226
Acyclovir nephrotoxicity (abst) ... 484
Adenine dinucleotides, phospholipase (abst) ... 490
Adenosine
transport and metabolism ... 1143
triphosphate, proliferation, PGE_2 (abst) ... 698
vasodilation, hypertensive kidney (abst) ... 1436
vasorelaxant effect of acetate ... 166
ADPKD ... 206
Adrenal steroids, sodium/excretion ... 37:S-97
Adrenalectomy, corticosterone levels ... 326
Adrenocorticotrophin
steroid-induced hypertension ... 37:S-34
Adrenocorticotropin
sodium intake and excretion of rabbits ... 37:S-97
Adriamycin, glomerular epithelial cells (abst) ... 1432
Aging and sodium homeostasis ... 37:S-107
Alanine, cadmium toxicity (abst) ... 1451
Albumin
binding inhibition, CRF (abst) ... 480
excretion, diabetic glomerulopathy ... 741
excretion, pregnancy (abst) ... 1437
synthesis, nephrotic syndrome ... 132
Albuminuria
causes in NIDDM ... 758
endothelial dysfunction, NIDDM (abst) ... 1433
octreotide administration in diabetes ... 805
Aldose reductase activity (abst) ... 492
Aldosterone
metabolism (abst) ... 512
sodium transport ... 255
Alkalinization urinary (abst) ... 1462
Allograft
cyclosporine therapy (abst) ... 1460
disease confirmed by biopsy (abst) ... 1460
Epstein-Barr virus (abst) ... 1439
histopathology ... 155
noninvasive monitoring (abst) ... 1470
survival rates (abst) ... 1464
Allopurinol, renal ischemia (abst) ... 1451
Alport familial nephritis ... 1629
Aluminoxamine removal in dialysis ... 1400
Aluminum
accumulation/distribution, iron (abst) ... 1433
bone disease, deferoxamine (abst) ... 1470
bone disease, dialysis ... 1374
bone disease, fluoride ... 1340
Ambulatory blood pressure
microalbuminuria ... 847
monitoring ... 37:S-24
Amino acids
children with ESRD ... 1016
metabolism in CRF (abst) ... 1446
neurotransmitters, hypertension ... 37:S-2
Aminoglycoside administration, cytokines (abst) ... 1435
Aminopeptidases, glomerular epithelial cells ... 1571
Ammonia production from hippurate (abst) ... 484
Ammoniagenesis, cisplatin-induced alterations ... 73
Amphotericin B toxicity ... 1588
Amyloid nephrosis (abst) ... 1473
Amyloidosis
β_2-microglobulin, cervical vertebrae ... 1646
β_2-microglobulin, dialysis (abst) ... 486
dialysis-related, Nephrology Forum ... 1416
Anemia
EPO therapy, CAPD/CCPD (abst) ... 504
EPO therapy, chronic renal failure (abst) ... 1464
EPO therapy, end-stage renal disease (abst) ... 1457
EPO therapy, impaired erythrocyte fluidity (abst) ... 506
Aneurysmal dilation, arterial hypertension ... 37:S-61
Angiotensin, urinary excretion (abst) ... 1435
Angiotensin converting enzyme (ACE) inhibition
ADPKD ... 206
arterial hypertension, diabetes ... 912
calcium channel blockers, diabetic nephropathy ... 904
diabetes, proteinuria (abst) ... 482
early diabetic nephropathy ... 883
exercise, proteinuria, IDDM (abst) ... 492
GBM, diabetic nephropathy (abst) ... 484
hemodynamics, proteinuria, glomerulonephritis (abst) ... 482
proteinuria reduction ... 1297
Angiotensin II
inhibition, mesangial cells (abst) ... 480
low-renin hypertension model ... 24
mesangial cells, IL-1β, TNF-α (abst) ... 491
natriuresis on felodipine ... 36:S-73
PDGF-induced expression, protein kinase C (abst) ... 484
phospholipase D, mesangial cells (abst) ... 490
protein synthesis, mesangial cells in vitro ... 124
vascular structure, blood pressure ... 37:S-51
Angiotensinogen gene expression in diabetes mellitus ... 796
Anti-DNA monoclonal antibodies ... 1690
Anti-glomerular basement membrane
antibody (abst) ... 1452

disease, TGF-β (abst) ... 1452
heparan sulfate antibody ... 115
nephritis (abst) ... 1430
Anti-mesangial cell antibodies (abst) ... 697
Anti-myeloperoxidase
PMN damage to endothelial cells ... 375
Anti-neutrophil cytoplasm antibodies (ANCA)
associated vasculitides (abst) ... 1442
glomerular inflammatory pathogenesis ... 375
idiopathic crescentic glomerulonephritis (abst) ... 1447
IgM, IgG and pulmonary hemorrhage ... 1304
vasculitis, HLA class II genes ... 1059
Anti-OKT3 antibody detection (abst) ... 509
Anti-tubular basement membrane disease (abst) ... 511
Antidiuretic hormone (abst) ... 483
Antihypertensive therapy
diabetic nephropathy ... 479 (abst), 904
diabetic rats ... 891
experimental diabetic nephropathy ... 898
Antioxidant enzymes, contrast media nephropathy ... 1008
Aortic aneurysm ... 37:S-61
Apoptosis in glomerulonephritis ... 607
Appetite and CAPD (abst) ... 503
Arginine vasopressin
NA transport regulation, CCD ... 255
oxytocin, in 3 cell lines (abst) ... 699
protein kinase C, Egr-1 mRNA induction (abst) ... 698
protein synthesis of MC in vitro ... 124
remnant kidney CCD ... 1150
Arterial hypertension
aneurysmal dilation ... 37:S-61
treatment ... 912
Arteriovenous
fistulas (abst) ... 1439
hemodiafiltration, tumor lysis syndrome (abst) ... 1467
Ascites, nephrogenic, children (abst) ... 1470
Atheromatosis, arterial SMC ... 37:S-87
Atherosclerotic vascular disease, hemodialysis (abst) ... 480
Atrial natriuretic factor
aortic smooth muscle (abst) ... 699
localization ... 334
pathophysiology ... 1115
plasma concentration, calcium (abst) ... 1444
potassium channels, angiotensin II (abst) ... 494
Atrial natriuretic peptide (ANP)
cGMP production, inner medulla ... 37
insulin-dependent diabetes ... 813
kinetics in cardiac dysfunction ... 1333
Autosomal-dominant polycystic kidney disease (ADPKD) ... 1311
Azotemia, serum protein binding ... 1707

Basement membrane proteins ... 620
Beta blockers
early diabetic nephropathy ... 883
proteinuria reduction ... 1297
β_2-microglobulin
amyloidosis of cervical vertebrae ... 1646
synthesis ... 486
verapamil, CAPD, diabetic nephropathy (abst) ... 1459
Bicarbonate, in terminal RF ... 369
Biopsy
allograft kidney disease (abst) ... 1460
cyclosporine therapy (abst) ... 508
percutaneous with using semiautomated device (abst) ... 485
transjugular ... 445
Bismuth, overdosage, renal damage (abst) ... 1432
Blood pressure
ambulatory, diabetes ... 847
angiotensin II, vascular structure ... 37:S-51
mineralocorticoid responsiveness (abst) ... 481
noninvasive continuous monitoring, dialysis (abst) ... 478
regulation in ren-2 rats ... 37:S-125
renal regulatory function (abst) ... 490
spectral analysis in uremia ... 37:S-14
variability, cardiovascular risk ... 37:S-24
Blood transfusion and suppressor cells ... 143
Bone disease
aluminum, dialysis ... 1374
aluminum, fluoride ... 1340
transplantation, loss of mass (abst) ... 509
transplantation, metabolism (abst) ... 507, 1456
transplantation, prednisone (abst) ... 508
transplantation (abst) ... 1441
Brain infarction (abst) ... 1462
Buffering capacity, intracellular proton and pH ... 43

Cadaver kidneys
evaluating donors (abst) ... 1471
recipient pool demographics (abst) ... 1467
Cadmium toxicity
magnesium depletion ... 1237
renal phosphate transport system (abst) ... 1451
Calcitriol, hyperparathyroidism hemodialysis (abst) ... 1443
Calcium
ANF plasma concentration, CRF (abst) ... 1444
intracellular, vitamin D, mesangial cells (abst) ... 479
intracellular oscillations, collecting duct (abst) ... 1434
phosphate binding therapy, CRF (abst) ... 501
renal disease progression ... 36:S-2
vitamin D therapy, hemodialysis (abst) ... 501
Calcium antagonists
arterial hypertension, diabetes ... 912
chronic renal disease ... 36:S-114
renal function ... 36:S-66
renal hemodynamics, glomerular function ... 36:S-43
renal tubular effects ... 36:S-49
transplantation ... 36:S-87
Calcium beverages, stone-forming potential of ... 139
Calcium carbonate
phosphate binding, hemodialysis (abst) ... 1456
phosphate reduction, dialysis (abst) ... 502
Calcium channel blockers
ACE inhibition, diabetic nephropathy ... 904
captopril (abst) ... 1467
pH and potential, in calcium transport ... 289
renal perfusion flow (abst) ... 493
Calcium nephrolithiasis (abst) ... 1449
Calcium oxalate
crystallization, urate and GAGs ... 149
saturation, RDT patients, nephropathy (abst) ... 1445
Calcium transport
pH, calcium channel blockers ... 289
sodium interrelationship ... 281
CAPD
β_2-microglobulin, verapamil (abst) ... 1459
catheter placement, peritonitis (abst) ... 1459
EPO therapy, peritoneal transport (abst) ... 1458
erythropoietin treatment (abst) ... 493
glucose and appetite (abst) ... 503

HCV infection (abst) 483
hypercholesterolemia (abst) 1459
hyperlipidemia, gemfibrozil (abst) 1456
lymphatic absorption, trapping 1668
$1,25(OH)_2D_3$, calcium (abst) 502
peritoneal catheter location (abst) 503
peritonitis (abst) 503
rHuEPO therapy (abst) 504
Safe Lock system (abst) 1463
toxic shock syndrome (abst) 1463
ultrafiltration, protein clearance (abst) 1436
Captopril
calcium channel blockers (abst) 1467
contrast media, renal function (abst) 1445
diabetic nephropathy (abst) 1466, 1473
long-term effect, uremia (abst) 1457
potassium plasma concentration (abst) 1457
prostaglandin production (abst) 512
Carbamylation alters LDL metabolism 1175
Carcinoma, renal cell, integrins 641
Cardiac dysfunction, ANP kinetics 1333
Cardiopathy, hypertensive 37:S-45
Cardiovascular risk factors
dietary salt 37:S-90
hypertension 37:S-24
renal grafting (abst) 507
Cardiovascular role of central monoamine neurons ... 37:S-8
Carnitine metabolism and chronic renal failure 1613
Carteolol, potassium plasma concentration (abst) 1457
Catecholamines and local anesthetics (abst) 479
C5b-9 complement proteins
glomerular mesangial cells (abst) 496
membranous nephropathy and C3dg 933
Cells
activation by IL-1 546
culturing renal 215
dendritic, immunophenotyping (abst) 489
development in kidney 657
graft-host migration, transplantation (abst) 488
plica type in proximal tubule (abst) 489
regulating oncogene proliferation (abst) 488
responses to ECM molecules 632
signaling by endothelin peptides 542
Cerebral regulation, thirst 37:S-102
Cervical amyloidosis 1646
cGMP
metabolism in renal cells 88
production, ANP-stimulated 37
CGS 13080 in cyclosporine nephrotoxicity 199
Chloride transport in mTAL, PAF-induced inhibition of 269
Cholesterol
hypertension, glomerular injury 1254
modulates proximal transport 983
Chronic hyponatremia 1662
Chronic purine aminonucleoside nephrosis (abst) 701
Chronic renal failure
albumin binding inhibition (abst) 480
anemia, EPO therapy (abst) 1464
calcium, ANF plasma concentration (abst) 1444
calcium acetate, phosphate binding therapy (abst) 501
carbamylation alters LDL metabolism 1175
carnitine metabolism 1613
children, sexual maturity (abst) 1471
enalapril (abst) 499
erythropoietin therapy (abst) 505
GH pituitary secretion 356
lipoprotein abnormalities, hemodialysis 1394
muscle protein, amino acid metabolism (abst) 1446
parathyroid hormone, phagocytosis 1501
survival rates (abst) 1456
tryptophan metabolism (abst) 1457
underweight patients, hemodialysis (abst) 1465
Cisplatin
nephrotoxicity 73
sulfonefluoresceine secretion (abst) 478
Clostridium difficile infection, uremia (abst) 503
Clusterin distribution in renal ablation 938
Collagen
production, glomerular mesangial cells (abst) .. 1452, 1462
type I DNA, tissue specific expression (abst) 706
type III glomerulopathy (abst) 1445
type IV gene transcription (abst) 706
Collecting duct
antigen localization (abst) 489
intracellular Ca, Na (abst) 1434
Complement activation
OKT3 treatment (abst) 1438
renal microcirculation (abst) 492
Conductivity method, post-dialysis dry weight 440
Confocal laserscan microscopy (abst) 1444
Contraluminal sulfate/oxalate exchanger (abst) 480
Contrast media as GFR markers (abst) 500
Cool temperature dialysate, LV function 961
Coronary artery disease, diabetic nephropathy (abst) ... 487
Cortex
epithelial, IL-8 production 191
epithelial cysts, human, in vitro 1222
monoclonal antibody to ganglioside 1638
Cortical collecting duct
fluoride flux 342
remnant kidney, response to AVP 1150
sodium channels, AVP, mineralocorticoids 255
Corticosteroids
ablative nephropathy, adrenalectomized rats 326
withdrawal, transplantation, children (abst) 1439
withdrawal, transplantation, cyclosporine (abst) 1440
Corticotropin-releasing factor, sodium intake 37:S-97
^{51}Cr-EDTA clearance
glomerular filtration rate ..... 1081, 1450 (abst)
IgA nephropathy (abst) 511
Cryoglobulins, IgG3, induced wire-loop lesions 65
Cuprophan dialyzer membrane (abst) 486
Cushing's syndrome 37:S-34
Cyclic-3′,5′-nucleotide PDE isozymes 88
Cyclic AMP
erythropoietin mRNA regulation 1581
metabolism in renal cells 88
Cyclosporin
idiopathic membranous glomerulonephritis (abst) 1438
IgA nephropathy (abst) 1452
Cyclosporine
diltiazem, transplantation (abst) 508
endothelin-1, mesangial cells 1713
felodipine, transplantation 36:S-82
isradipine, transplantation (abst) 507
laminin expression (abst) 705
nephrotoxicity .. 199, 484 (abst), 486 (abst), 487 (abst), 507 (abst), 1432 (abst)
nephrotoxicity, verapamil (abst) 1473

proximal tubular cells (abst) ... 1451
renal biopsy changes (abst) ... 508
sodium retention ... 1599
steroid withdrawal, transplantation (abst) ... 1440
transplantation (abst) ... 1460
vascular responsiveness, renin (abst) ... 1451
Cysteinyl leukotrienes, renal synthesis ... 1543
Cystine urolithiasis, treatment (abst) ... 510
Cystinuria, 2-mercaptopropionylglycine (abst) ... 510
Cysts
immunohistological origin (abst) ... 488
overexpressed c-*myc* in *cpk* mouse kidneys ... 317
renal cortex epithelial, in vitro ... 1222
Cytokines
aminoglycoside administration (abst) ... 1435
glomerulonephritis (abst) ... 497
hemodialysis, Nephrology Forum ... 683
interferon gamma, adhesion of PMN (abst) ... 696
NO synthase, steroids (abst) ... 697
paracrine, tubulointerstitial fibroblasts ... 14
Cytomegalovirus, graft rejection (abst) ... 489
Cytoskeleton of smooth muscle cells ... 37:S-87
Cytosolic redox state of NADH/NAD+ ... 778

1,25 dihydroxycholecalciferol
glucose intolerance, hemodialysis ... 1049
1,25-dihydroxyvitamin D
in renal disease ... 161
1,25 dihydroxyvitamin D_3
cellular immunity, hemodialysis (abst) ... 1470
$1,25(OH)_2D_3$
calcium therapy, CAPD (abst) ... 502
Deferoxamine, aluminum osteodystrophy (abst) ... 1470
Deflazacort therapy, transplantation (abst) ... 1439
Dendritic cells, immunophenotyping (abst) ... 489
Denmark, dialysis-associated hepatitis C (abst) ... 502
Dexamethasone (abst) ... 705
Diabetes
ACE inhibition, proteinuria (abst) ... 482
antihypertensive treatment (abst) ... 479
arterial hypertension ... 912
glomerular N-deacetylase ... 763
kallikrein, renin gene expression ... 789
KTA/SPK transplant, renal failure ... 924
microalbuminuria, early glomerular disease ... 840
peritoneal clearances (abst) ... 1459
thromboxane β_2 excretion (abst) ... 486
Diabetes, insulin dependent
exercise, ACE inhibitors (abst) ... 492
glomerular structure ... 741
glomerular thromboxane receptors ... 992
glomerular volume measurement ... 1085
glycemic control, renal function ... 920
microalbuminuria as prognostic indicator ... 836
natriuresis, ANP ... 813
nephropathy and hypertension ... 723, 736
plasma prorenin, microvascular disease (abst) ... 1437
sodium-lithium countertransport ... 855, 877
Diabetes, non-insulin dependent
albuminuria ... 758, 1433 (abst)
electron microscopy of glomeruli ... 749
survival rates ... 731
Diabetes insipidus
nephrogenic X-linked gene (abst) ... 1430
Diabetes mellitus
GFR, renal plasma flow, NIDDM ... 829
progressive renal disease ... 36:S-38
renin, angiotensinogen gene expression ... 796
streptozotocin-induced (abst) ... 700
tubular alteration, metabolic control (abst) ... 486
Diabetic glomerulosclerosis ... 396
Diabetic nephropathy
ACE inhibition, beta-blockers, diuretics ... 883
ACE inhibition, calcium channel blockers ... 904
ACE inhibition, GBM (abst) ... 484
antihypertensive therapy ... 499 (abst), 898
bone metabolism, transplantation (abst) ... 507
CAPD, β_2-microglobulin, verapamil (abst) ... 1459
captopril (abst) ... 1466, 1473
clinical study (abst) ... 1448
coronary artery disease (abst) ... 487
cytosolic ratio of NADH/NAD^+ ... 778
erythrocyte NaLi countertransport ... 862
glomerular basement membrane (abst) ... 703
glomerular hyperfiltration ... 822, 1620
glycemic control, Oslo study ... 920
heparan sulfate expression (abst) ... 1432
heparin sulfate proteoglycans ... 1070
hypertension ... 723, 736
inheritance ... 719
LDL binding to mesangial cells ... 1161
lipids, cellular Na/H antiport activity ... 872
lipids, lipoproteins, apolipoprotein (abst) ... 1449
NIDDM patients (abst) ... 1448
peripheral nerve conduction (abst) ... 1449
platelet activating factor (abst) ... 491
proteolytic lysosomal enzymes, hypertrophy ... 966
streptozotocin induced ... 768
transplantation (abst) ... 509
Diacylglycerol, ECM synthesis (abst) ... 700
Dialysate, cool temperature, LV function ... 961
Dialysis
acute renal failure (abst) ... 510
amyloidosis, Nephrology Forum ... 1416
calcium carbonate, phosphate reduction (abst) ... 502
continuous noninvasive BP monitoring (abst) ... 478
cytokine production, Nephrology Forum ... 683
erythropoietin pharmokinetics (abst) ... 482
granulocyte LAM-1, MAC-1 modulation ... 388
sodium balance, monitoring (abst) ... 1444
sports as rehabilitation (abst) ... 488
Dietary protein
ablative nephropathy ... 326
chronic transplant rejection ... 183
hyperfiltration ... 1620
renin, subtotal nephrectomy (abst) ... 496
Dietary salt as cardiovascular risk factor ... 37:S-90
Dietary sodium and elderly ... 37:S-107
Diltiazem, transplantation (abst) ... 508
Distal tubule, calcium transport ... 281
Diuretics
early diabetic nephropathy ... 883
thiazide, PAH transport system (abst) ... 478
Dopamine
endogenous, renal function (abst) ... 481
renal hemodynamics (abst) ... 1445
renal sympathetic nerves (abst) ... 491
Dry weight, post-dialysis, measurement ... 440
Dyslipoproteinemia, renal failure (abst) ... 499

Echocardiography, hemodialysis, rHuEPO therapy (abst) 1469
Egr transcription factors 550
Eicosanoids
  mesangial proliferation 554
  production and protein uptake 1000
Electron microscopy 749
Electronic data processing in renal units (abst) 513
Enalapril
  chronic nephropathy (abst) 499
  compared with felodipine 36:S-78
  renal, systemic sensitivity (abst) 1436
End-stage renal disease
  with ADPKD 1311
  children (abst) 1456
  children and nutrition 1016
  diabetes and hemodialysis (abst) 1448
  essential hypertension 36:S-33
  morphological study (abst) 499
Endothelial cells
  anti-MPO-stimulated PMN damage 375
  lymphocyte adhesion (abst) 705
  matrix modulation of 560
Endothelin
  cytosolic calcium, L-arginine (abst) 695
  infrarenal aortic cross clamping (abst) 1443
  peptides 542
  plasma levels, Korean hemorrhagic fever (abst) 1455
Endothelin-1
  production in cultured mesangial cells 350
  receptor antagonist 1713
Endothelium-derived relaxing factor
  hypertension 37:S-73
  in renal function 403
Endotoxin-induced renal failure (abst) 498
Enteric hyperoxaluria (abst) 512
Enzymes and regulation of sodium balance 37:S-114
Epithelial cells
  cortical, IL-8 production in 191
  development 657
  IL-6, GM-CSF and PDGF-B (abst) 482
  laminin, fibronectin (abst) 701
  LLC-PK1, cyclic-3′,5′-nucleotide PDE 88
  magnesium, cadmium toxicity 1237
  morphogenesis and tenascin 629
  osteonectin expression 56
Epstein-Barr virus, allograft (abst) 1439
Erythrocytes
  glomerulonephritis (abst) 482
  morphology (abst) 487
  sodium-lithium countertransport (abst) 1442
Erythropoietin
  age-dependent production (abst) 481
  ambulatory peritoneal dialysis (abst) 505
  anemia, CRF (abst) 1464
  anemia, erythrocyte fluidity (abst) 506
  anemia, hemodialysis (abst) 506
  anemia, pre-dialysis renal hemodynamics 384
  antithrombin III, fibrinogen, protein C (abst) 1471
  CAPD (abst) 493
  chronic renal failure (abst) 505
  dialysis (abst) 482
  erythrocyte osmotic resistance (abst) 506
  exercise, pre-dialytic uremia (abst) 504
  hemodialysis, hormone changes (abst) 1468
  hemodialysis, iron (abst) 496
  hemodialysis (abst) 504, 1458
  hemodynamics (abst) 505
  hypertension (abst) 495
  mRNA regulation and cAMP 1581
  parathyroid hormone, noninflammatory ARF (abst) 488
  porphyria cutanea tarda (abst) 1443
  preuremia (abst) 504
  subcutaneous (abst) 506
  transplantation (abst) 507, 509
Essential fatty acid depletion, glomerulonephritis 1245
Essential hypertension and ESRD 36:S-33
European Hantavirus nephropathy (abst) 1431
Excretion
  albumin, pregnancy (abst) 1437
  sodium, cerebral regulation of thirst 37:S-102
  sodium, tubular Na-K-ATPase 37:S-118
  urinary angiotensin (abst) 1435
  urinary protein, normal individuals (abst) 1437
Exercise
  proteinuria, ACE inhibitors, IDDM (abst) 492
  uninephrectomy, renal function (abst) 479
Extracellular matrix
  binding of LDL 1161
  cellular responses to 632
  development 657
  epithelial organ morphogenesis 629
  graft-versus-host disease (abst) 700
  during nephrogenesis 641
  production regulated by TGF-β1 1213
  synthesis (abst) 700
  synthesis and morphine 1560
  transforming growth factor-β 557
Extracellular volume, parathyroid hormone (abst) 1443
Extracorporeal shock wave lithotripsy (abst) 1473

Familial Mediterranean fever 414
Fanconi syndrome (abst) 1453
Felodipine
  acute renal failure 36:S-94
  angiotensin II, natriuresis 36:S-73
  compared with enalapril 36:S-78
  with cyclosporine after transplant 36:S-82
  renal function 36:S-54, 36:S-100, 36:S-106, 36:S-110
Ferrioxamine, removal in dialysis 1400
Ferritin levels, hemodialysis (abst) 1472
Fibroblasts, tubulointerstitial 14
Fibronectin
  laminin, epithelial cells (abst) 701
  production, mesangial cell 396
  synthesis, gene transcription (abst) 706
  synthesis, TGF-β, MC cultures (abst) 703
Filopedia, function of 665
Fish oil supplementation, hemodialysis patients (abst) 1446
Fistula dysfunction in rapid hemodialysis 1292
Fluoride
  aluminum-induced bone disease 1340
  flux in rabbit CCD 342
Focal segmental glomerulosclerosis
  lovastatin (abst) 1453
  mesangial expression of ICAM-1 951
  in MGN 428
Folate binding protein in proximal tubule 50
Fosinopril, nifedipine, in diabetic rats 891

Furosemide
infusion, lithium (abst) 1430
papillary osmolality (abst) 494

Gadolinium-DTPA, glomerular filtration rate 1595
Ganglioside, expression in renal cortex 1638
Gemfibrozil, hyperlipidemia, CAPD (abst) 1456
Gentamicin nephrotoxicity (abst) 1462
Glomerular basement membrane
diabetic nephropathy, HSPG 1070
diabetic nephropathy (abst) 484, 703
HSPG antibodies and proteinuria 115
Glomerular cells
development 657
proliferation (abst) 297, 701
Glomerular efferent arteriole outflow segment (abst) 481
Glomerular endothelial cells
culture 1506
HIV infection 956
Glomerular epithelial cells
adriamycin (abst) 1432
aminopeptidases A and N 1571
cell density, growth regulation (abst) 698
matrix production, TGF-β1 regulation 1213
mRNa 72kDa type IV collagenases (abst) 704
Glomerular filtration rate
calcium antagonists 36:S-43
contrast media as clinical marker (abst) 500
dietary protein, hyperglycemia 1620
estimation by intraperitoneal ^{99m}Tc DTPA 450
hyperfiltration predicts nephropathy 822
IgA nephropathy (abst) 512
kallikrein, renin gene expression 789
measurement, gadolinium-DTPA 1595
measurement, iothalamate 1081
measurement, rapid in small animals 435
measurement, subcutaneous infusion 1701
measurement (abst) 511
newly-presenting NIDDM 829
serotoninergic hepatorenal reflex (abst) 496
Glomerular hemodynamics
platelet activating factor (abst) 495
progressive renal disease 36:S-8
Glomerular hyperfiltration (abst) 494
Glomerular immune deposits 1690
Glomerular lesions, wire-loop 65
Glomerular mesangial cells
collagen production (abst) 1452
glucose, insulin, somatostatin (abst) 702
identification, in vivo, in vitro (abst) 696
immune complex, collagen production (abst) 1462
interleukin-6 (abst) 698
Glomerular mesangial matrix
glycoprotein synthesis (abst) 705
turnover and proteinases 671
Glomerular N-deacetylase in diabetes 763
Glomerular permselectivity 310
Glomerular sclerosis, growth factors 36:S-15
Glomerular structure
insulin-dependent diabetes 741
mesangial failure 533
Glomerular thrombomodulin activity 1170
Glomerular thromboxane receptors in diabetes 992
Glomerular tissue factor, thromboxane synthesis 361
Glomerular vascular components, parietal podocyte 211
Glomerular volume, measurement in IDDM 1085
Glomeruli
electron microscopy in NIDDM 749
isolated perfused, renin release in 275
Glomerulonephritis
15-S-HETE antagonizes LTB4 1155
acute extracapillary necrotic (abst) 511
anti-glomerular basement membrane antibody (abst) . 1452
apoptosis 607
autoimmune 5
C5b-9 complement proteins (abst) 496
cytokines, growth factors (abst) 497
differential diagnosis (abst) 484
essential fatty acid depletion 1245
focal glomerulosclerosis 428
hemodynamics, proteinuria (abst) 483
hepatitis B virus associated, pathology (abst) 1453
histological changes, biopsy (abst) 494
idiopathic necrotizing 375
integrins (abst) 480, 701
membranoproliferative, steroid therapy 1606
muscle-specific actin 1134
pathogenesis (abst) 482
PDGF and 590
polyanion charge and RBC (abst) 487
treatment with TGF-β antagonists 566
Glomerulopathy, collagen type III (abst) 1445
Glomerulosclerosis
cholesterol, hypertension 1254
glomerular cell proliferation and PDGF 297
graft-versus-host disease (abst) 700
idiopathic membranous glomerulonephritis 428
mesangial expression, ICAM-1 in FSGS 951
nifedipine (abst) 485
prevention with TGF-β antagonists 566
Gluconeogenesis, cisplatin-induced alterations 73
Glucose
glomerular redox changes 778
heparan sulfate proteoglycan synthesis (abst) 705
intolerance, 1,25$(OH)_2D_3$, hemodialysis 1049
mesangial cell fibronectin production 396
TGF-β gene in proximal tubule 107
transport, cadmium toxicity (abst) 1451
Glutamine and ammonia formation (abst) 484
Glycolysis and vasorelaxant effect of acetate 166
Glycoprotein synthesis (abst) 705
Glycosaminoglycans
calcium oxalate urolithiasis 149
IGF enhanced biosynthesis 1262
GM-CSF in renal epithelial cells (abst) 482
Goodpasture's disease (abst) 704
Gout (abst) 1449
Graft-versus-host disease
cytomegalovirus (abst) 489
glomerulosclerosis, extracellular matrix (abst) 700
lupus nephritis 5
Granulocyte LAM-1 and MAC-1 modulation, dialysis ... 388
Growth factors
glomerular sclerosis 36:S-15
glomerulonephritis (abst) 497
Growth hormone
growth retarded uremic children (abst) 1461
secretion in CRI 356

11-HSD, regulation of sodium balance 37:S-114

25-hydroxyvitamin D
nephrotic syndrome, children (abst) ... 1450
Hantavirus nephropathy (abst) ... 1431
HCV infection in CAPD (abst) ... 483
Heart rate, spectral analysis ... 37:S-14
Heat-shock protein 73-kDa, renal localization ... 1204
Hematuria, children (abst) ... 1471
Hemodiafiltration
hemodialysis comparison ... 1035
multipurpose system (abst) ... 501
Hemodialysis
aluminoxamine, ferrioxamine removal ... 1400
aluminum bone disease ... 1374
amyloidosis pathogenesis (abst) ... 486
calcium, vitamin D therapy (abst) ... 501
calcium carbonate, phosphate binding (abst) ... 1456
carnitine metabolism ... 1613
cellular immunology (abst) ... 495
coagulation inhibitors (abst) ... 1470
cytokine production, Nephrology Forum ... 683
diabetic patients, clinical features (abst) ... 1448
elderly patients (abst) ... 502
EPO therapy, hormone changes (abst) ... 1468
EPO therapy, iron (abst) ... 496
EPO therapy, life quality (abst) ... 504
EPO therapy, porphyria cutanea tarda (abst) ... 1443
EPO therapy, RBC (abst) ... 494
EPO therapy (abst) ... 505, 506, 1458
excessive thirst (abst) ... 1446
fish oil supplements (abst) ... 1446
hemodiafiltration, comparison ... 1035
heparin therapy (abst) ... 502
hepatitis C risk factors ... 1055
hippuric acid excretion (abst) ... 1433
hyperparathyroidism (abst) ... 491
hypoxemia, fibrinolytic system (abst) ... 1472
impaired platelet TSP release (abst) ... 482
leukocyte counts, membrane type (abst) ... 479
lipid peroxidation risk (abst) ... 480
lipoprotein abnormalities ... 1394
measurement of dry weight ... 440
morbidity, mortality factors ... 1029
non-occlusive mesenteric obstruction (abst) ... 498
$1,25(OH)_2D_3$, glucose intolerance ... 1049
peripheral venous compliance ... 1041
prescription, delivery ... 1023
rapid, fistula dysfunction ... 1292
recirculation in (abst) ... 1455
survival rates, blood pressure control ... 1286
survival rates (abst) ... 1456
thyroid function (abst) ... 1469
underweight patients, CRF (abst) ... 1465
venous/arterial systems, plasma volume (abst) ... 1435
ventilatory, metabolic changes ... 1064
volumetrically-controlled circuit ... 1366
Hemodynamics
Ca antagonists ... 36:S-43
dopaminergic modulation (abst) ... 1445
erythropoietin therapy (abst) ... 505
felodipine, enalapril compared ... 36:S-78
glomerular, progressive renal disease ... 36:S-8
glomerulonephritis, ACE inhibition (abst) ... 483
high volume hemofiltration (abst) ... 1434
PKD ... 206
pre-dialysis, anemia, EPO therapy ... 384
proteinuria, beta-blockers, ACE inhibitors ... 1297
venous compliance, ultrafiltration (abst) ... 1434
Hemofiltration, endotoxin shock hemodynamics (abst) ... 1434
Hemoperfusion, aluminoxamine, ferrioxamine removal ... 1400
Hemorrhagic fever renal syndrome (abst) ... 1454, 1455
Henoch-Schönlein purpura nephritis (abst) ... 1453
Henoch-Schönlein vasculitis (abst) ... 1468
Heparan sulfate
anti-GBM, proteinuria ... 115
diabetic nephropathy ... 1070, 1432 (abst)
proteoglycan, synthesis (abst) ... 705
Hepatitis B
glomerulonephritis, pathology (abst) ... 1453
recombinant vaccine, nonresponders (abst) ... 1447
transplantation (abst) ... 1466
Hepatitis C
dialysis, Denmark (abst) ... 502
dialysis, Venezuela ... 1055
Herpes simplex (abst) ... 1464
HETE metabolism and smooth muscle cells ... 37:S-67
High-affinity folate binding protein ... 50
High-density lipoprotein metabolism in uremia ... 1653
Hippurate, renal ammonia production (abst) ... 484
Hippuric acid and hemodialysis (abst) ... 1433
HLA class II genes
ANCA associated vasculitis ... 1059
IMG ... 175
Hollow fiber dialyzers ... 1383
Human immunodeficiency virus (HIV) ... 956
Human leukocyte antigen typing by RFLP method (abst) ... 1471
Hydrated clearance of gadolinium-DTPA ... 1595
Hydroxyeicosatetraenoic acids ... 37:S-67
Hypercalcemia and sarcoidosis (abst) ... 510
Hypercalciuria ... 139, 1449 (abst)
Hypercholesterolemia
CAPD (abst) ... 1459
hypertension ... 1254
Hyperfiltration
^{51}Cr-EDTA clearance (abst) ... 1450
dietary protein, hyperglycemia ... 1620
Hyperglycemia, potassium, diabetes (abst) ... 1463
Hyperlipidemia
diabetic nephropathy (abst) ... 1449
extrahepatic lipogenesis (abst) ... 1438
gemfibrozil, CAPD (abst) ... 1456
LDL binding to mesangial cells ... 1161
Hyperparathyroidism
calcitriol, hemodialysis (abst) ... 1443
hemodialysis (abst) ... 491
renal NA handling (abst) ... 1441
Hypertension
amino acid neurotransmitters ... 37:S-2
arterial, treatment ... 912
arterial and aneurysmal dilation ... 37:S-61
children (abst) ... 1471
ERDF (nitric oxide) response ... 37:S-73
erythropoietin therapy (abst) ... 495
essential, end-stage renal disease ... 36:S-33
felodipine, acute renal effects ... 36:S-106
IDDM ... 723, 736
left ventricular and vascular amplifiers ... 37:S-38
myocardial hypertrophy (abst) ... 484
Na/H exchange activity (abst) ... 494
Na/K-ATPase inhibition (abst) ... 493

pathogenesis in ADPKD ... 206
proteinuria, IgA nephropathy (abst) ... 511
renin-angiotensin system ... 24, 1469 (abst)
salt-resistant/sensitive (abst) ... 1433
sodium-lithium countertransport ... 855
spontaneous, therapy with diabetes ... 898
steroid-induced and ACTH ... 37:S-34
survival rates, hemodialysis ... 1286
therapy, diabetic nephropathy (abst) ... 499
thromboxane production (abst) ... 497
transplantation (abst) ... 508
Hypertensive cardiopathy ... 37:S-45
Hypertrophy, myocardial
pathogenesis (abst) ... 484
Hypertrophy, renal
octreotide administration in diabetes ... 805
proteolytic enzymes, diabetes ... 966
Hyperuricemia
renal function, gout (abst) ... 1449
transplantation (abst) ... 1461
Hypoalbuminemia (abst) ... 1450
Hypokalemia (abst) ... 1450
Hyponatremia ... 1662
Hypotension, cool temperature dialysate, LV function ... 961
Hypoxemic-induced renal dysfunction ... 80

Idiopathic membranous glomerulonephritis
childhood ... 1606
cyclosporin (abst) ... 1438
focal glomerulosclerosis ... 428
HLA-class II genes ... 175
IgA nephropathy
anti-mesangial cell antibody (abst) ... 697
^{51}Cr-EDTA clearance (abst) ... 511
cyclosporin (abst) ... 1452
epidermal growth factor (abst) ... 699
GFR, urinary protein excretion (abst) ... 512
pathogenesis, Nephrology Forum ... 1720
pathology (abst) ... 1453
proteinuria, hypertension (abst) ... 511
sodium-lithium countertransport (abst) ... 1442
IgG
ANCA, IgM, pulmonary hemorrhage ... 1304
binding, mesangial cells, C1Q complement (abst) ... 1435
cryoglobulins, induce wire-loop lesions ... 65
IgM
ANCA, IgG, pulmonary hemorrhage ... 1304
Immune complex, glomerular mesangial cells (abst) ... 1462
Immunosuppressive therapy
blood transfusion ... 143
parathyroid status (abst) ... 509
transplantation, renal function (abst) ... 1440
transplantation (abst) ... 509
Indomethacin
acute potassium load excretion (abst) ... 1434
long-term effect, uremia (abst) ... 1457
Infrarenal aortic cross clamping (abst) ... 1443
Injury
CD8$^+$ cell-mediated glomerular ... 1517
glomerular, antihypertensive therapy ... 891
glomerular, hypertension ... 1254
glomerular, IL-1, mesangial cells ... 595
glomerular, mesangial response ... 542
glomerular, proteinuria ... 840
glomerular, remnant kidney rats ... 1527
mesangial cell ... 1134
oxidant renal, contrast media induced ... 1008
proximal tubule, acute PO_4 depletion ... 1494
TxA_2 receptor blockade, lupus nephritis ... 973
vessel wall, nephrotic syndrome (abst) ... 1436
Inner medullary collecting duct (abst) ... 483
Insulin
kallikrein and renin gene expression ... 789
response, endogenous opioids (abst) ... 1442
secretion in uremia with $1,25(OH)_2D_3$ ... 1049
Insulin-like growth factor-1
enhanced biosynthesis of PGs/GAGs ... 1262
tyrosine phosphorylation, oncoprotein (abst) ... 697
Integrated double-bag CAPD systems (abst) ... 503
Integrins
activation, leukocyte ... 613
glomerulonephritis (abst) ... 480, 701
human kidney ... 641
laminin E8 ... 650
recognition motifs ... 245, 645
Intercellular cell adhesion molecule-1
leucocyte-endothelial cell adhesion (abst) ... 702
mesangial expression in FSGS ... 951
Interferon production (abst) ... 1455
Interleukin-1
cell activation ... 546
IL-8 generation, mesangial cells (abst) ... 695
mesangial cell proliferation monocytes (abst) ... 697
mesangial cells ... 595
renal localization after hemorrhage (abst) ... 699
Interleukin-2
Wegener's granulomatosis (abst) ... 490
Interleukin-4
minimal change nephrotic syndrome (abst) ... 1453
Interleukin-6
regulates mesangial cell growth ... 604
renal epithelial cells (abst) ... 482
secretion, glomerular mesangial cells (abst) ... 698
Interleukin-8
production in renal cortical epithelia ... 191
Interstitial fibrosis
chronic purine aminonucleoside nephrosis (abst) ... 701
collagen synthesis, gene expression (abst) ... 703
pathogenesis (abst) ... 482
Interstitial nephritis (abst) ... 485
Intracellular
adhesion molecule-1, inflammatory response ... 617
buffering and pH ... 43
Intradialytic blood volume trends (abst) ... 1446
Intraglomerular proteinases, protein uptake (abst) ... 704
Intrauterine device, copper and renal failure (abst) ... 485
Iopentol, renal failure (abst) ... 500
Iothalamate, measures GFR ... 1081
Iron, aluminum accumulation/distribution (abst) ... 1433
Ischemia
experimental chronic renal ... 1676
myocardial, membrane phospholipids ... 37:S-79
renal disease progression ... 36:S-21
trifluoperazine, allopurinol in rats (abst) ... 1451
Isradipine, cyclosporine, transplantation (abst) ... 507

Kallikrein and renin gene expression in diabetes ... 789
Korean hemorrhagic fever (abst) ... 1454, 1455

5-lipooxygenase in obstructive nephropathy ... 100

Lactoferrin antibodies (abst) 478
LAM-1 granulocyte receptor, dialysis 388
Laminin
  E8 and $\alpha 6\beta 1$ integrin 650
  fibronectin, epithelial cells (abst) 701
Lead nephrotoxicity 1192
Left ventricular
  contractility, cool temperature hemodialysis 961
  hypertrophy, hypertension 37:S-38
Leucine oxidation, chronic metabolic acidosis 1535
Leucocyte-endothelial cell adhesion (abst) 702
Leukocytes
  integrin activation 613
  kinetics in plasmapheresis (abst) 479
  transmigration across endothelium (abst) 706
Leukotrienes
  obstructive nephropathy 100
  renal synthesis, metabolism 1543
Leukotrine B4
  antagonized by 15-S-HETE 1155
Ligands
  binding integrins to 645
  extraction by deproteinization 1707
Lipids
  abnormality, transplantation (abst) 1461
  cellular Na/H antiport activity 872
  peroxidation risk with hemodialysis (abst) 480
Lipogenesis, hepatic (abst) 1438
Lipoprotein abnormalities in hemodialysis 1394
Lisinopril, renal, systemic sensitivity (abst) 1436
Lithium, furosemide infusion (abst) 1430
Liver function after kidney grafting 420
LLC-PK1 epithelial cells
  cyclosporine toxicity (abst) 507
  isozymes of cyclic-3′,5′-nucleotide PDE 88
Local anesthetics and catecholamines (abst) 479
Loop diuretics and thiazide interaction (abst) 478
Loop of Henle, thin (abst) 483
Lovastatin 1453
Low-density lipoprotein
  binding to mesangial cells 1161
  carbamylation alters metabolism 1175
  heparan sulfate proteoglycan synthesis (abst) 705
  mesangial cell growth (abst) 699
Low-renin hypertension model 24
Lower body negative pressure 37:S-29
Luminal membrane of distal tubule
  calcium transport, calcium channel inhibitors 289
  calcium transport, sodium 289
Lupus glomerulonephritis (abst) 1445
Lupus nephritis
  pathogenesis ..... 5, 495 (abst)
  TxA_2 receptor blockade 973
Lupus nephritis (abst) 488
Lymphatic absorption, trapping in CAPD 1668
Lymphocytes
  adhesion to endothelial cells (abst) 705
  stimulation by β_2m (abst) 486
Lyotropism and vasorelaxant effect of acetate 166

2-mercaptopropionylglycine, cystinuria (abst) 510
6-methylprednisolone therapy, transplantation (abst) ... 1439
MAC-1 granulocyte receptor, dialysis 388
Macrophages, nephritis, MC injury (abst) 1430
Magnesium
  depletion and cadmium toxicity 1237
  thiazide-induced osteocytes (abst) 496
Mathematical simulation of hemodialysis 1366
Matrix modulation of microvascular cells 560
MDCK cells, Na/K-ATPase activity 455
Medulla, inner, cGMP production 37
Membrane phospholipid metabolism 37:S-79
Membranous nephropathy
  C3dg, C5b-9, immune pathogenesis 933
  immune deposits, Nephrology Forum 1090
Mesangial cell proliferation
  endothelium mediated (abst) 697
  glomerulonephritis 590
  IL-1, IL-6, monocytes (abst) 697
  low density lipoprotein (abst) 699
  morphine 1560
  thromboxane A_2, prostaglandins 554
  transforming growth factor-β (abst) 483, 696
Mesangial cells
  angiotensin II, IL1-β, TNF-α (abst) 491
  angiotensin inhibition (abst) 480
  binding of LDL 1161
  ET-1 production in cultured rat MC 350
  ET-1 receptor antagonist, cyclosporine 1713
  expression of ICAM-1 in FSGS 951
  fibronectin production and high glucose 396
  glomerular macrophages, renal ablation (abst) 1431
  glomerular tuft structure 533
  HIV infection 956
  IgG, IL-6 production (abst) 695
  IL-1 595
  IL-6 regulates growth 604
  injury 1134
  matrix modulation of 560
  PDGF and 581
  phospholipase activation (abst) 490
  protein synthesis in vitro, vasoactive agents 124
  response to glomerular injury 542
  smooth muscle α-actin (abst) 696
  TNF-α 600
  vitamin D, intracellular calcium (abst) 479
Mesangium, pathobiology of 524
Mesothelial cells, osmotic solute toxicity 1280
Metabolic acidosis
  chronic, proteolysis, leucine oxidation 1535
  neutral phosphate-induced 1182
Metabolism
  adenosine transport 1143
  cAMP and cGMP in renal cells 88
  during hemodialysis 1064
Microalbuminuria
  diabetes, ambulatory BP 847
  as prognostic indicator in NIDDM 836
Microcirculation, renal, complement activation (abst) ... 492
Microscopic polyarteritis ..... 490 (abst), 700 (abst), 1059
Microvascular cell differentiation in vitro 560
Milk, stone-forming potential of 139
Mineralocorticoids, Na transport in CCD 255
Minimal change nephrotic syndrome
  interleukin-4 (abst) 1453
  multiple brain infarction (abst) 1462
MiniMed portable pump 1701
Moesin, in cellular functions 665

Monoclonal antibodies
anti-DNA, lupus ... 1690
ganglioside ... 1638
immunoscintigraphy, human renal tumors (abst) ... 492
production, mesangial cell matrix (abst) ... 703
Monohydroxylated fatty acids ... 37:S-67
Morphine, effects on mesangial cells ... 1560
Mouse renin gene in transgenic rats ... 24, 37:S-125
Muscle-specific actin, glomerulonephritis ... 1134
Myeloperoxidase and lactoferrin antibodies (abst) ... 478
Myocardial
hypertrophy, pathogenesis (abst) ... 484
ischemia, membrane lipid metabolism ... 37:S-79
Myofibroblast, biology of ... 530

Na^+ coupled amino acid transport
proximal tubule cells (abst) ... 485
Na/H exchange
alkaline intracellular pH (abst) ... 497
antiport activity, cellular ... 872
cellular, antiport activity ... 872
cloning of cDNAs encoding (abst) ... 485
hypertension (abst) ... 494
Na/K-ATPase
activity in MDCK cells ... 455
inhibition, vasopression, hypertensive plasma (abst) ... 493
natriuresis ... 37:S-118
NADH/NAD^+, cytosolic redox state of ... 778
Natriuresis
angiotensin II on felodipine ... 36:S-73
insulin-dependent diabetes ... 813
tubular Na-K-ATPase ... 37:S-118
Nephritis
experimental lupus, pathogenesis ... 5
Henoch-Schönlein purpura (abst) ... 1453
interstitial, copper IUCD (abst) ... 485
macrophages, MC injury (abst) ... 1430
stages, passive anti-GBM (abst) ... 1430
Nephrogenesis, integrins in ... 641
Nephron, glomerular vascular components ... 211
Nephropathia epidemica
hemorrhagic fever, renal syndrome (abst) ... 510
Nephropathy
diabetes, nitrendipine (abst) ... 479
Hantavirus, European (abst) ... 1431
IgA, pathogenesis, Nephrology Forum ... 1720
obstructive, 5-lipooxygenase ... 100
radiocontrast induced ... 1408
Nephrosclerosis
decompensated benign, differential diagnosis (abst) ... 484
Nephrotic syndrome
albumin synthesis, measurement ... 132
histopathology (abst) ... 1466
minimal change, brain infarctions (abst) ... 1462
minimal change, IL-4 (abst) ... 1453
prednisolone (abst) ... 1467
serum 25-hydroxyvitamin D, children (abst) ... 1450
vegetarian diet (abst) ... 1446
vessel wall injury, thrombotic response (abst) ... 1436
vitamin D levels ... 161
Nephrotoxic nephritis
depletion of CD8+ cells ... 1517
essential fatty acid depletion ... 1245
Nephrotoxicity
acyclovir, cyclosporin (abst) ... 484
amphotericin B ... 1588
contrast media ... 1274
cyclosporine ... 199, 1432 (abst)
lead, high-dose ... 1192
Neurovascular junctions, sympathetic ... 37:S-56
Neutral phosphate-induced metabolic alkalosis ... 1182
Neutrophils
anti-MPO-stimulation and endothelial cells ... 375
proteinase 3, Wegener's granulomatosis (abst) ... 1431
Nifedipine
contrast media, renal function (abst) ... 1445
fosinopril ... 891
glomerulosclerosis (abst) ... 485
Nitrendipine, diabetic nephropathy (abst) ... 479
Nitric oxide
EDRF, glomerular, tubular function ... 1549
hypertension ... 37:S-73
synthase, cytokines, steroids (abst) ... 697
Nitroprusside, dopamine, acute renal failure (abst) ... 493
Non-occlusive mesenteric obstruction (abst) ... 498
Nuclear signaling by ET peptides ... 542
Nutrition, in children with ESRD ... 1016

Obstructive nephropathy, 5-lipooxygenase ... 100
Obstructive uropathy, renal plasma flow ... 403
Octreotide administration, diabetic rats ... 805
OKT3 treatment, complement activation (abst) ... 1438
Oncoproteins, IGF-1 induced (abst) ... 697
Opioids, endogenous (abst) ... 1442
Orange juice with calcium, stone-forming ... 139
Organic marine hydrocolloid (abst) ... 512
Orosomucoid concentrations, glomerular function ... 310
Orthostatism, vascular resistances ... 37:S-29
Oslo IDDM study ... 920
Osmotic solutes toxicity ... 1280
Osteonectin, tubular epithelial cells ... 56
Ovarian carcinoma, acute renal failure (abst) ... 1468
Oxidant renal injury, contrast media-induced ... 1008
Oxygen-dependent changes, EPO mRNA levels ... 1581
Oxytocin, arginine, in 3 cell lines (abst) ... 699

p-aminohippurate (PAH) transport
expression (abst) ... 495
thiazide, loop diuretics (abst) ... 478
Pancreas-kidney transplantation ... 924
Parathyroid hormone
chronic renal failure, phagocytosis ... 1501
EPO, noninflammatory ARF (abst) ... 488
extracellular volume (abst) ... 1443
metabolism, uremia (abst) ... 501
protein kinase C activity (abst) ... 486
transplantation (abst) ... 509
Parietal podocyte, glomerular vascular components ... 211
Peptides
binding integrins to ligands ... 645
cGMP production, inner medulla ... 37
Peripheral neuropathy
diabetes (abst) ... 1449
electrophysiology, transplantation (abst) ... 1463
Peripheral venous system in hemodialysis ... 1041
Peritoneal dialysis
aluminum bone disease ... 1374
anemia, rHuEPO therapy (abst) ... 504
erythropoietin therapy (abst) ... 493, 505
increased ultrafiltration (abst) ... 489

low volume, infants (abst) 1465
lymphatic absorption, trapping..... 1668
osmotic solute toxicity 1280
solute, fluid transport 1320
vitamin-D_3 adsorption to bags (abst) 503
Peritoneal hemosiderosis, ascites, children (abst)..... 1470
Peritonitis
CAPD catheter placement (abst) 1459
CAPD integrated double-bag systems (abst) 503
sclerosing, procollagen detection (abst)..... 503
Pertussis-toxin-sensitive nucleotide binding (abst) 695
Phagocytosis, CRF, hyperparathyroidism..... 1501
Phosphate
depletion, tubule cell injury 1494
reduction, calcium carbonate, dialysis (abst)..... 502
transport, cadmium intoxication (abst) 1451
transport, growth hormone (abst)..... 1454
Phospholipase
activation in mesangial cells (abst)..... 490
activation PDGF receptors..... 575
Phospholipid metabolism and myocardial ischemia .. 37:S-79
Platelet activating factor
diabetic nephropathy (abst) 491
glomerular hemodynamics, nephrectomy (abst) 495
inhibition of mTAL function 269
Platelet aggregation activity, EPO therapy (abst)..... 506
Platelet derived growth factor
expression in transgenic model 584
glomerulosclerosis 297
mesangial cell mediation..... 581
mesangial cell proliferation in GN 590
protein kinase C, Ang II (abst) 484
protein kinase C, Egr-1 mRNA induction (abst)..... 698
receptors, phospholipase C activation..... 575
signaling, heterodimeric, homodimeric receptors 571
Platelet derived growth factor-β
hypertrophied myocardium (abst) 484
renal epithelial cells (abst) 482
Platelet TSP release, impaired, hemodialysis (abst)..... 482
Platelets, thromboxane synthesis, glomerular TF..... 361
Plica cells, proximal tubule (abst) 489
Pneumonia, CsA-treated transplantation (abst)..... 1460
Polycythemic kidney transplant patients
Ca modulate, erythropoiesis (abst)..... 1441
Polycystic kidney disease
ACE-inhibition 206
overexpressed c-*myc*, *cpk* mouse kidneys..... 317
Polymorphonuclear leucocytes
anti-MPO-stimulated damage, endothelial cells..... 375
interferon gamma, cytokines, endothelium (abst)..... 696
Porphyria cutanea tarda, erythropoietin therapy (abst) . 1443
Post-dialysis dry weight, conductivity measurement 440
Potassium
excretion of acute load, indomethacin (abst)..... 1434
plasma levels, bicarbonate effect, terminal RF 369
plasma levels, Carteolol, Captopril (abst) 1457
plasma levels, diabetes, hyperglycemia (abst)..... 1463
transport, mTAL, PAF-induced inhibition of 269
Pre-dialysis patients, anemia, EPO therapy 384
Prednisolone
nephrotic syndrome, children (abst)..... 1467
Prednisone
transplantation, necrosis femoral head (abst) 508
Pregnancy, albumin/creatinine ratio (abst) 1437
Preuremia, erythropoietin therapy (abst)..... 504
ProANFs 1-30 and 31-67 localization 334
Procollagens, sclerosing peritonitis (abst)..... 503
Prostaglandins
mesangial cell proliferation..... 554
production, captopril (abst) 512
Protein
clearance, CAPD, ultrafiltration (abst)..... 1436
ligand extraction, azotemic sera..... 1707
synthesis, MC, vasoactive agents 124
synthesis, thromboxane A2 (abst) 1442
uptake, eicosanoid production 1000
Protein kinase C
Ang II, PDGF induced (abst)..... 484
Egr-1 mRNA induction (abst) 698
parathyroid hormone (abst) 486
vascular smooth muscle cell growth (abst) 696
Proteinase 3 antibodies
lactoferrin antibodies (abst) 478
Proteinuria
ACE inhibition, reduced renal mass (abst) 482
anti-GBM heparan sulfate antibody..... 115
children (abst)..... 1471
early diabetic glomerular disease..... 840
exercise, ACE inhibitors, IDDM (abst)..... 492
glomerulonephritis, ACE inhibition (abst)..... 483
hemorrhagic fever renal syndrome (abst)..... 1455
IgA nephropathy, hypertension (abst)..... 511
reduction, beta-blocker, ACE inhibitor 1297
as renal disease marker 36:S-26
Proteoglycans, IGF enhanced biosynthesis..... 1262
Proteolysis, chronic metabolic acidosis..... 1535
Proteolytic lysosomal enzymes 966
Protooncogenes, myocardial hypertrophy (abst)..... 484
Proximal tubule
adenosine transport and metabolism 1143
convoluted, transport mechanisms (abst) 492
cyclosporine (abst) 1451
folate binding protein activity 50
glucose, TGF-β gene 107
immunosuppressive agents, TNF-α (abst)..... 1431
injury, acute PO_4 depletion 1494
local anesthetics, catecholamines (abst) 479
Na coupled amino acid transport (abst)..... 485
plica cells (abst) 489
sodium transport modulation 983
Pseudohyperkalemia, thrombocytosis (abst)..... 1450
Puberty onset, chronic renal failure (abst) 1471
Pulmonary hemorrhage, ANCA, IgM and IgG 1304
Puromycin aminonucleoside
adriamycin, glomerular epithelial cells (abst)..... 1432
lovastatin, FSGS (abst)..... 1453
Pyelonephritis, pathobiology 1356

Radiocontrast media
captopril, nifedipine (abst) 1445
intracellular tubular detection, rats (abst) 500
nephropathy..... 1008, 1274, 1408
Recombinant human erythropoietin
anemia, ESRD (abst) 1457
CAPD (abst)..... 504
clinical study, Turkish (abst) 1472
hemodialysis, anemia (abst)..... 506
hemodialysis, cell-mediated immunity (abst)..... 1458
hemodialysis, EKG findings (abst)..... 1469
muscle blood flow, ERD patients (abst)..... 1444

pharmokinetics in dialysis (abst) 482
pre-dialysis, peripheral lymphocytes (abst) 506
pre-dialysis (abst) 1466
subcutaneous/intravenous routes (abst) 505
Red blood cells
glomerular polyanion charge (abst) 487
hemodialysis, erythropoietin therapy (abst) 494
Renal artery stenosis (abst) 512
Renal failure
aluminum-induced bone disease 1340
bismuth overdosage (abst) 1432
dyslipoproteinemia (abst) 499
endotoxins, prostaglandins, PAF (abst) 498
familial Mediterranean fever 414
felodipine 36:S-100
glomerular hemodynamics 36:S-8
hypoxemic, thiophosphate WR-2721 80
iopentol (abst) 500
KTA/SPK transplant, diabetes 924
nephropathia epidemica/hemorrhagic fever (abst) 510
pathogenesis (abst) 482
progression, ADPKD 1311
progression, calcium 36:S-2
progression, clinical evaluation of 36:S-26
progression, current concepts, therapy 36:S-61
progression, diabetes mellitus 36:S-38
progression, ischemia 36:S-21
reversible, copper IUCDs (abst) 485
terminal, bicarbonate, plasma K 369
Renal plasma flow
newly-presenting NIDDM 829
role in obstructive uropathy 403
Renin
gene expression, diabetes mellitus 796
gene expression, kallikrein, diabetes 789
plasma, dietary protein, nephrectomy (abst) 496
secretion, calcium channel blockers (abst) 493
secretion, isolated perfused glomeruli 275
Renin-angiotensin system
aldosterone, EPO-related hypertension (abst) 1469
aldosterone, sodium balance 37:S-114
converting enzyme inhibition (abst) 478
hypertension 24
nephropathy, progression (abst) 496
proteinuria, orthostasis (abst) 1437
Restriction fragment length polymorphism (abst) 1471
Rhabdomyolysis, acute renal failure (abst) 1451

Safe Lock system, CAPD (abst) 1463
Saline, intravenous, chronic hyponatremia 1662
Salt restriction, glomerular injury 1527
Sarcoidosis, hypercalcemia (abst) 510
Scleroderma, renal manifestations Nephrology Forum 462
Septicemic renal failure (abst) 498
Serotonin, protein synthesis of MC in vitro 124
Signal transduction and Egr transcription factors 550
Simvastatin therapy, transplantation (abst) 1441
Smooth muscle α-actin, mesangial cells (abst) 696
Smooth muscle cells
arterial, atheromatosis 37:S-87
arterial, HETE metabolism 37:S-67
Sodium
balance regulation, enzymes 37:S-114
CCD channels, AVP regulation 255
excretion and thirst 37:S-102
homeostasis and aging 37:S-107
intake and excretion of rabbits 37:S-97
monitoring balance, dialysis (abst) 1444
reabsorption, tubular Na-K-ATPase 37:S-118
renal handling, hyperparathyroidism (abst) 1441
retention with cyclosporine 1599
Sodium-calcium transport
distal tubule luminal membrane 281
Sodium dependent dicarboxylate transporter (abst) 495
Sodium-lithium countertransport
diabetes 877
diabetic nephropathy 862
hypertensive IDDM 855
IgA nephropathy (abst) 1442
Solute and fluid transport, peritoneal dialysis 1320
Sorbitol synthesis (abst) 492
Spectral analysis, BP, heart rate in uremia 37:S-14
Sphingomyelinase modulates proximal transport 983
Sport as rehabilitation, dialysis patients (abst) 488
Steroids
membranoproliferative glomerulonephritis, childhood 1606
sodium intake and excretion of rabbits 37:S-97
withdrawal, transplantation, cyclosporine (abst) 1440
Stone-forming potential of calcium beverages 139
Straight proximal tubules, transport mechanism (abst) 492
Streptozotocin, diabetes mellitus (abst) 700
Sulfate/oxalate transport system (abst) 480
Sulfonefluoresceine secretion
cisplatin-treated rat kidneys (abst) 478
Suppressor cells, induction by blood transfusion 143
Swan Neck Tenckhoff catheters (abst) 1465
Sympathectomy, arterial pressure 37:S-19
Sympathetic neurovascular junctions 37:S-56
Systemic lupus erythematosus 5, 1690

Tc-99m monoclonal antibody 138H11
immunoscintigraphy (abst) 492
^{99m}Tc DMSA, DTPA
intraperitoneal, GFR assessment 450
Tenascin
epithelial morphogenesis 629
isoform expression, mouse kidney (abst) 705
synthesis (abst) 701
Thiazide therapy
loop diuretics, PAH transport system (abst) 478
magnesium, osteocyte production (abst) 496
Thiophosphate WR-2721
hypoxemic renal dysfunction 80
Thirst
hemodialysis patients (abst) 1446
renal sodium excretion 37:S-102
Thrombocytosis, pseudohyperkalemia (abst) 1450
Thrombomodulin activity in glomeruli 1170
Thrombospondin
macrophage uptake, apoptotic neutrophils (abst) 704
platelet release, hemodialysis (abst) 482
TNF 679
Thromboxane
CGS 13080 inhibition, cyclosporine 199
glomerular receptors, vasoconstriction, diabetes 992
production, renovascular hypertension (abst) 497
synthesis in platelets, glomerular TF 361
Thromboxane A_2
mesangial cell proliferation 554
protein synthesis, human mesangial cells (abst) 1442

receptor blockade in murine lupus nephritis 973
synthesis 1483
Thromboxane β_2
excretion, diabetes mellitus (abst) 486
Thyroid function
ESRD, hemodialysis (abst) 1472
hemodialysis (abst) 1469
Tissue proteinases 671
Total hip replacement, transplantation (abst) 491
Toxic shock syndrome, CAPD (abst) 1463
Transforming growth factor-β
antagonists 566
anti-glomerular basement membrane disease (abst)... 1452
epithelial cell matrix production 1213
extracellular matrix 557
fibronectin synthesis, mesangial cell cultures (abst) ... 703
glucose in proximal tubule 107
mesangial cell proliferation (abst) 483, 696
Transfusion, blood, and suppressor cells 143
Transgenic rats carrying mouse renin gene
blood pressure regulation 37:S-125
low-renin hypertension model 24
Transjugular renal biopsy 445
Transplantation
arteriovenous fistulas, post-biopsy (abst) 1439
bone loss, cortical (abst) 509
bone metabolism (abst) 507, 1441, 1456
Ca antagonists 36:S-87
Ca modulate, EPO, polycythemic kidney (abst) 1441
case reviews (abst) 1460
chronic rejection and dietary protein 183
corticosteroid withdrawal, children (abst) 1439
cyclosporine, isradipine (abst) 507
cyclosporine, steroid withdrawal (abst) 1440
cyclosporine (abst) 486, 487, 508, 1460
deflazacort, 6-methylprednisolone therapy (abst) 1439
diabetic nephropathy (abst) 509
diltiazem (abst) 508
electrophysiologic changes, neuropathy (abst) 1463
erythropoietin therapy (abst) 507, 509
felodipine, cyclosporine interaction 36:S-82
graft-host cell migration (abst) 488
hepatitis B (abst) 1466
herpes simplex, varicella zoster (abst) 1464
HLA mismatching, graft survival (abst) 1464
hypertension (abst) 508
hyperuricemia (abst) 1461
immunosuppression, renal functional reserve (abst) .. 1440
immunosuppression (abst) 509
infection (abst) 1460
interstitial pneumonia, CsA-treated (abst) 1460
KTA versus SPK, diabetes 924
lipid abnormality (abst) 1461
liver function after 420
mixed lymphocyte culture (abst) 1468
prednisone, necrosis femoral head (abst) 508
renal function, donor/recipient (abst) 508
simvastatin therapy, hypercholesterolemia (abst) 1441
survival rates (abst) 1472
TNF-α plasma levels (abst) 481
total hip replacement (abst) 491
Transport mechanisms
Na^+ coupled amino acid, proximal tubule cells (abst) . 485
proximal convoluted, straight tubules (abst) 492
regulating oncogene proliferation (abst) 488
Transtubular potassium concentration gradient (abst) .. 1450
Trifluoperazine, allopurinol, renal ischemia (abst) 1451
Tryptophan metabolism, chronic renal failure (abst) ... 1457
Tubular epithelium
development 657
isolation of cDNA 220
Tubular necrosis, regeneration, Nephrology Forum 226
Tubular transport
effects of Ca antagonists 36:S-49
nitric oxide EDRF 1549
urate, after uninephrectomy 1349
Tubulointerstitial fibroblasts 14
Tumor lysis syndrome (abst) 1467
Tumor necrosis factor
cultured rat mesangial cell (abst) 698
thrombospondin 679
Tumor necrosis factor-α
after transplantation (abst) 481
mesangial cells 600
production, immunosuppressive agents (abst) 1431
Wegener's granulomatosis (abst) 490, 700
Tyrosine phosphorylation, IGF-1 induced (abst) 697

Ultrafiltration
hollow fiber dialyzers 1383
peritoneal dialysis (abst) 489
transcapillary, CAPD, protein clearance (abst) 1436
venous/arterial systems, plasma volume (abst) 1435
venous compliance, hemodynamics (abst) 1434
Ultrasound
renal artery stenosis (abst) 512
Uninephrectomy
renal function, childhood (abst) 1437
renal function, exercise (abst) 479
renal function, proteinuria, living donors (abst) 498
tubular urate transport 1349
Urate
calcium oxalate urolithiasis 149
transport, after uninephrectomy 1349
Uremia
clostridium difficile infection (abst) 503
heart rate, BP variability, spectral analysis 37:S-14
high-density lipoprotein metabolism 1653
insulin secretion with $1,25(OH)_2D_3$ 1049
parathyroid hormone metabolism (abst) 501
pre-dialytic, EPO therapy, exercise (abst) 504
Urinary alkalinization, gentamicin (abst) 1462
Urinary complement in membranous nephropathy 933
Urinary protein excretion
GFR, IgA nephropathy (abst) 512
orthostasis, renin-angiotensin (abst) 1437
Urodilatin with dopamine, acute renal failure (abst) 493
Urolithiasis ..... 149, 1449 (abst)

1,25-vitamin D_3 (abst) 479
Vaccine, hepatitis B, nonresponders (abst) 1447
Varicella zoster, transplantation (abst) 1464
Vascular cell adhesion molecule-1 (abst) 702
Vascular resistance
enhanced, hypertension 37:S-38
regional, lower body negative pressure 37:S-29
Vascular structure, angiotensin II 37:S-51
Vasculitis
ANCA associated, HLA class II genes 1059
survival rates (abst) 1447

Vasoactive
agents, protein synthesis of MC in vitro 124
hormones, MC growth, protein synthesis (abst) 702
Vasoconstriction
glomerular, thromboxane receptors, diabetes 992
radiocontrast-induced nephropathy 1408
Vasodilation
effects of acetate 166
pre-dialysis, EPO therapy, anemia 384
Vegetarian diet, nephrotic syndrome (abst) 1446
Venezuela, dialysis-associated hepatitis C 1055
Ventilation during hemodialysis 1064
Verapamil
cyclosporine toxicity (abst) 1473
intraperitoneal, CAPD (abst) 1459
long-term effect, uremia (abst) 1457
Vitamin D
free and total, renal disease 161
intracellular Ca, mesangial cells (abst) 479
Volume depletion, contrast media nephropathy 1008

Water fluxes in hollow fiber dialyzers 1383
Wegener's granulomatosis . 478 (abst), 490 (abst), 700 (abst), 1059, 1304, 1431 (abst), 1435 (abst)
Wire-loop lesions, induced by IgG3 cryoglobulins 65

X-linked nephrogenic diabetes insipidus (abst) 1430